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Biorelevant in vitro release/dissolution tests are designed to predict the in vivo behavior
of a drug and are crucial in understanding its in vivo performance. Currently, there is no
standardized compendial in vitro release testing methods or regulatory guidance’s for
release/dissolution testing of implants due to their complex physiological locations.

Furthermore, existing compendial methods do not capture the local release profile of
‘novel’ parenterals in physiological low fluid volume surrounding areas.

Long acting and in situ forming implants with orthobiologic proteins and peptides have
increased over the past few decades due to a better understanding of genetic
engineering. One of these products, INFUSE® Bone Graft (Medtronics, MN, USA), is an
implant which helps in bone regeneration at the trauma site and is comprised of a) an
absorbable collagen sponge (ACS) and b) recombinant human bone morphogenetic
protein-2 (rhBMP-2). INFUSE® Bone Graft is an FDA approved product for acute, open
shaft tibial fractures, lumbar spinal fusions and sinus or ridge augmentations in the jaws.
The evaluation of implant products such as INFUSE® Bone Graft requires a good
understanding of local and systemic release in vivo in order to ensure safe, effective,
and predictable product performance.

The primary goal of this study is to develop a predictive ‘biorelevant’ release model,
which factors in clinically relevant physiological parameters suitable for studying and
effectively predicting extended release of implants, using INFUSE Bone Graft® as our
model implant. A novel biorelevant in vitro model was designed and tested. The model
was observed to be discriminatory between two different carrier formulations of rhBMP2 using a model independent approach - similarity factor (f2). Additionally, a high
throughput assay to quantify rhBMP-2 release using high performance liquid
chromatography with UV/VIS detection was also developed and validated. Successful
completion of this study facilitated an in vitro release study design that incorporated the

complex biorelevant parameters of implant dosage forms, the model will offer crucial
insights into biological performance, and aid in developing methods to characterize
release of other similar dosage forms.

CHAPTER 1

1 INTRODUCTION
Parts of this chapter have been drawn from an editorial published in
J Pharmacovigilance,(Biswas and Halquist, 2016)

1.1 BACKGROUND
1.1.1 Dissolution testing and its significance
Dissolution testing is the utilization of surrogate in vitro conditions to mimic in vivo
release conditions of a dosage form (Azarmi et al., 2007). This is achieved with the help
of dissolution medium, dissolution apparatus and a robust study design (US
Pharmacopeia, 2011b). The aim of dissolution testing is to develop a test that
represents the drugs in vivo dissolution profile but is reproducible and easy to perform in
the lab. It is a performance verification test for a dosage form and helps in being an
evaluative quality control tool in the commercial manufacturing process (Dressman and
Krämer, 2005; Siewert et al., 2003). A dissolution test can be developed early on during
the pre- clinical stages of a drug when formulation design changes are made to the
dosage form such as incorporation of excipients or other components (Lipka and

1

Amidon, 1999). Effects of inclusion or exclusion of such components in the formulation
can then be studied with the help of a simple in-house dissolution test instead of using
in vivo animal models at each step. A dissolution test for oral dosage forms ensures
minimal batch-to-batch variability and hence works as a check that the dosage form
meets the requisite regulatory and quality standards. It can also be applied in examining
methodically the stability of a dosage form (Nazzal and Khan, 2006). The stability of
dosage forms can be affected by changes in storage temperatures, shelf time duration,
minor changes in pH, moisture content at the location of storage and even light
conditions (Carstensen, 1974; Yoshioka and Stella, 2000). The US Pharmacopeia
provides chapters <711> and <724> as test chapters for methods to perform dissolution
and drug release respectively (Formulary, 2012; US Pharmacopeia, 2011a). These
tests are therefore part of a series of acceptance criteria tests required by regulatory
agencies like US Food and Drug Administration (FDA) and required to be included in
the public specification repertoire of tests (US Pharmacopeia, 2011b).

Dissolution tests are also an essential requirement for establishing bioequivalence and
biowaivers for generic drug products (Chen et al., 2001; US Pharmacopeia, 2011b).
Bioequivalence as defined by US FDA, is the establishment of equivalence of drug
bioavailability (BA) between two different formulations (Chen et al., 2001). Biowaivers
are waivers for in vivo bioavailability and bioequivalence studies by substituting in vitro
data such as in vitro dissolution studies (Löbenberg and Amidon, 2000; Yu et al., 2002).
Biowaivers are mostly granted to generic drugs based on their Biopharmaceutics
Classification System (BCS) (Yu et al., 2002). Highly soluble and highly permeable
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Class I drugs, such as immediate release (IR) oral dosage forms often fall into the
category where a request for biowaivers can be made based on rapid in vitro dissolution
data (Yu et al., 2002). Dissolution tests are therefore used in establishing
bioequivalence between formulations, during scale up and post approval changes
(SUPAC) or minor formulation changes (Rudman et al., 1996; Yu, 2008). An essential
requirement for bioequivalence is for the dissolution test to be discriminatory between
different formulations (such as tablets and capsules) and different strengths (Qureshi,
2006). The dissolution method is thus selected based on its ability to discriminate
between different formulations (Anand et al., 2011). At least 12 units of each type of
formulation needs to be tested to establish bioequivalence between the test and
reference product (Anand et al., 2011). United States Pharmacopeia (USP) suggests a
list of seven apparatuses for dissolution testing in its chapter <711> on dissolution (US
Pharmacopeia, 2011a). The general guidance provided by the FDA for establishing
bioequivalence of a generic drug product is to perform a dissolution test by initially
selecting one of the seven available USP methods (USP apparatus I to VII). If the USP
methods are not predictive of the in vivo profile or not discriminatory between the
formulations of the dosage form the next approach should be to select a test method
suggested by FDA. In case the FDA method is not available or it is found that the
results of the test method are not representative of the in vivo profile or/and is not
discriminatory a dissolution method should be developed (Anand et al., 2011).

Chapter <1092> of the USP describes in detail the guidelines for ‘the dissolution
procedure’ (US Pharmacopeia, 2011b). A primary requirement for a dissolution study

3

design is its ease of transfer between laboratories and reproducibility. Once an in vitro
dissolution test has been successfully established, variability of in vitro and in vivo data
is particularly significant in analyzing batch variability, process variables, formulation
variables and even analytical variability (Qureshi and McGilveray, 1999). Dissolution
method development is thus a delicate balance between the individual components of
medium, apparatus and a robust, predictive and applicable study design (Biswas and
Halquist, 2016).

1.1.2 Components of a dissolution / release test study
design
Dissolution medium:
Selection of the dissolution medium is one of the most significant steps in development
of a dissolution method (Galia et al., 1998). The dissolution media would serve the
study design in a better way if it were representative of the fluid conditions surrounding
the dosage form in vivo. Hence, for ‘special’ dosage forms such as implants and
parenteral it becomes critical to select a biorelevant dissolution/release medium.
Biorelevance is the simple representation of the in vivo physiological conditions in the
study design. This helps in establishing clinical relevance for the test procedure and in
evaluating further how a change in behavior of the dosage form actually is affected by
the in vivo factors.
Common factors to consider while selecting the medium are its pH and buffering
capacity, osmolality, and changes in pH with changes in temperature conditions (Iyer et
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al., 2007c). The dissolution medium also needs to provide sink conditions to the dosage
form. Sink conditions can be defined as the volume of media three times the volume in
which the dosage form is in saturated solution (US Pharmacopeia, 2011b). Use of
surfactants is permitted if it improves the solubility of the drug substance in the media.
USP generally discourages using organic mixtures as a dissolution medium unless
justifications are provided (US Pharmacopeia, 2011b). The medium in some cases also
needs to be de-aerated to remove any bubbles, which might interfere with the diffusion
and exchange of drug substance with the media.
For IR solid oral dosage forms the volume recommendation are 500- 1000mL in basket
or paddle apparatus(US Pharmacopeia, 2011a). The volume can also be raised to 2-4L
if the media needs to meet the sink conditions for the drug substance such as in poorly
soluble drugs Class II BCS drugs. In such cases addition of surfactants such as
polysorbate 80 for solubilization of the drug substance can be justified (US
Pharmacopeia, 2011a). Recommended pH requirements for the media in case of solid
oral dosage forms are between pH 1.2 – 7.5 to simulate gastric and intestinal fluids (US
Pharmacopeia, 2011a). The general choice of dilute hydrochloric acid, and various
simulated fluids such as Fasted State Simulated Intestinal Fluid (FaSSIF- for fasted
state intestinal media) and Fed State Simulated Intestinal Fluid (FeSSIF - for fed state
intestinal media) with incorporation of components such as enzymes, bile salts to make
the media more biorelevant has been observed so far (Galia et al., 1998; Jantratid et al.,
2008; Marques, 2004). To summarize dissolution media needs to provide sink
conditions and solubility to the dosage form, stability during analytical method validation
with minimum interferences to the quantitation of the drug substance, ruggedness and

5

should not interfere with the study design of the dissolution method being discriminatory
between formulations. Added to this if a dissolution medium is biorelevant in its
composition such as osmolality, inorganic ion composition and pH it helps in
establishing clinical relevance. Factors such as changes in pH of the media, with the
release of drug substance and with changes in temperature, especially around the
physiological range of 37 °C needs to be evaluated.
Dissolution apparatus:
The choice of the dissolution apparatus is generally based on the type of the dosage
form. The design of formulation, its unique release, diffusion and disintegration
mechanism also affect the selection of the model apparatus. For solid oral dosage
forms the most recommended apparatus are USP apparatus 1 and 2 (Brown et al.,
2009; Klancke, 2003). The basket apparatus also called as USP apparatus 1, with
sinkers is recommended for formulations that float such as capsules. It has nominal
volumes of 1 – 2L (US Pharmacopeia, 2011a). The paddle apparatus or USP apparatus
2 is recommended for tablets. Sinkers may also be used with this model if required.
Apparatus 3 is the reciprocating cylinder and apparatus 4 is the flow through cell
respectively. They are often also used for testing modified or delayed release oral
dosage forms. Apparatus 3 allows the flexibility of using different types of media in
series for monitoring drug release studies. Apparatus 4 is generally used for drug
substances with low solubility. The various agitation or stirring factors that are of
significance in the different apparatuses are: rotation speed for apparatus 1 and 2, dip
rate for reciprocating cylinder/apparatus 3 and flow rates for flow through cell/apparatus
4. These factors ensure proper mixing, release and dissolution of the drug substance in

6

the dissolution media. Generally in all the apparatuses the recommended temperature
for the dissolution media is the physiological temperature of 37°C (US Pharmacopeia,
2011a).

Dissolution study design:
The final element, which ties together the choice of dissolution medium and the
apparatus selection, is the study design. Dissolution study design requires a
comprehensive understanding of the formulation design; the drug substance or active
pharmaceutical ingredient (API); release mechanism of the API from the formulation;
the rate limiting step: i.e. dissolution, release or permeability and finally the scope of the
dissolution method to solve the specific problem in question. The US Pharmacopeia has
set required acceptance criteria for dissolution tests which need to be followed
especially in cases of establishing bioequivalence of generics (US Pharmacopeia,
2011a). Generally the testing is done through three stages: S1, S2 and S3 and the
percentage of drug substance dissolved or released is a critical parameter. At stage S1
at least 6 units of the dosage forms are tested and none of the units should have the
total amount dissolved less than 5% of the label claim of the API. At stage S2, 6 units
are tested again however; at this stage comprising S1+S2 (i.e 12 samples) none of the
units should have less than 15% of the API label claim dissolved. Stage S3 is the last
stage and a total of 12 units are tested. So by stage S3 a total of 24 units of each
formulation are required to be tested. For a successful dissolution test not more than 2
units can be less than 15% of the mentioned label claim of the API and in the whole
batch of 24 units no unit can be less than 25% (US Pharmacopeia, 2011b).
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Apart from the number of samples tested another key factor in the study design is the
sampling method and the selection of sampling time points. Sampling can be performed
manually or automated sampling can be used. For automated sampling requisite
validation is required for use of the method in conjunction with the apparatus since
automated sampling often requires the inclusion of an additional sampling probe
component into the dissolution experimental set up. For IR solid oral dosage forms time
points of 15, 20, 30, 45 and 60 min are recommended by USP in chapter <1092>, since
in most of the cases 85 -100% of API is dissolved in 30- 45min (US Pharmacopeia,
2011b). For extended release and novel dosage forms such as parenteral, it is crucial
the study design includes sampling time points such that they bracket the different
phases of release: especially in cases of dosage forms with ‘multiphasic’ release. This
is essential so that the in vitro dissolution or release method might adequately represent
the in vivo release profile of the drug.

Consideration for the analytical test methodology is the last and significant factor in the
design of a successful dissolution test (Ermer and Miller, 2006; Wang et al., 2006).
Generally UV spectrophotometric methods are recommended for sample analysis over
HPLC methods because of their ease of use and time efficiency (US Pharmacopeia,
2011b). HPLC methods though high-throughput require an initial time investment for
method development and validation as compared to UV spectrophotometric methods.
However, HPLC methods offer certain advantages over simple UV methods primarily
when the formulation contains interfering excipients at the same wavelength as the drug
substance. A well-developed HPLC method could allow for separation of the excipient
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peak from the drug substance peak and help in precise and accurate quantitation of the
API. In addition a stability indicating HPLC method also allows the detection of
degradants in the dissolution or release media. Detection of appearance of degradants
would indicate to researcher either to replace the dissolution media with fresh media in
a timely fashion or re-evaluate the dissolution conditions to encourage stability of the
released drug substance (Iyer et al., 2007c). Other physical components that a
dissolution and analytical scientist should be aware of are the use of filtration and
centrifugation if required, as essential tools for sample analysis. The general USP
guidelines suggest avoiding the use of centrifugation (since it establishes a
concentration gradient in the supernatant) as a means of particulate material separation
in the dissolution or release media, and instead suggest the use of in line or off line
filters before sample analysis (US Pharmacopeia, 2011b).

1.1.3 ‘Release Testing’: Application of dissolution testing to
complex non-oral dosage forms
Non-oral dosage forms often encompass complex dosage forms such as parenterals,
implants, drug eluting stents, transdermal patches, liposomes, microspheres and nano
particles as injectables. These dosage forms are frequently characterized by complex
delivery systems and release mechanisms of the active drug substance (Gregoriadis
and Florence, 1993; Widder et al., 1978). With the rapid advances in genetic
engineering and recombinant DNA technology in the past few decades the active drug
moiety can also be a sensitive and labile biotherapeutic protein, which adds an
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additional layer of complexity to the drug product. In the case of non-oral dosage forms
dissolution/release tests that ensure performance verification of the drug are called “in
vitro release tests” rather than dissolution tests (Burgess et al., 2002a). The rationale
being often non-oral dosage forms are placed at diverse locations in the body e.g.
ocular implants in the chambers of eye, transdermal patches on skin, drug-eluting stents
in coronary arteries, suppositories in rectum or urethra, subcutaneous or intramuscular
implants all of which have dramatically different physiological milieu (Seidlitz et al.,
2011b). As a result the action of the drug depends to a large extent on its release or
retention from the dosage form. For example in the bone regenerating indication
INFUSE® Bone Graft the local retention and in turn controlled release of the bone
morphogenetic protein from the collagen carrier scaffold is directly related to bone
growth and bone density scores (Yasko et al., 1992).

Frequently in ‘novel’ dosage forms such as liposomes, implants, drug eluting stents the
drug substance is carried in complex delivery systems e.g. carrier based biopolymer
scaffolds such as collagen matrix, injectable biodegradable polymer based matrix which
solidifies at the site of action e.g. Atrigel®, in a lipid based system such as liposomes
(Malik et al., 2010). These complex delivery systems help in ascertaining drug release
in a controlled manner and in some cases for extended periods of time. The release
mechanism in each of the above cases is unique. It significantly affects the
maintenance of the therapeutic levels of the drug substance in the blood/systemic
circulation or in some models e.g. INFUSE® Bone Graft specifically at the local site of
action. In drug modalities like transdermal patches the release needs to occur through
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multiple membranes and needs to penetrate through the skin and layers of external
barriers before reaching the site of action (Barry, 2001). In subcutaneous and
intramuscular implants the blood flow conditions might affect the time taken by the drug
to reach the targeted site. Therefore, to list a few factors the release mechanism, rate of
release, and the time required by the drug to reach the site of action varies notably in
each unique case. Hence the in vivo performance of these complex (non-oral) dosage
forms can be characterized more precisely by carefully designed in vitro release tests,
with design space criteria that are ‘biorelevant’. Although initially dissolution tests were
designed as a tool for oral immediate release products they have also been used as a
means of ensuring biotherapeutic performance or quality characterization within a
defined design space criteria for implant like products. Similar to oral IR dosage forms
non-oral/parenteral dosage forms utilize release tests as a means of quality control and
testing variation in formulations.

1.1.4 Significance of biorelevance while designing release
study designs in ‘novel’ dosage forms:
The significance of biorelevance for novel dosage forms such as implants increases
manifold due to their complex release and pharmacokinetic tissue distribution of the
drug substance e.g. varying viscous ocular compartments in case of ocular implants.
Biorelevant parameters, which are often of significant influence, are criteria pertaining to
the physiological positioning of the dosage form and site of action of the drug.
Incorporation of biorelevance in an in vitro release test would involve a) recognition of
the ‘crucial’ in vivo parameters that significantly affect release of the drug from the
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dosage form and b) selection/inclusion of these parameters in the in vitro design space.
These in vivo factors are frequently temperature, blood flow rates, tissue barriers, and
acidity of the microenvironment, osmolarity and pH. These parameters can considerably
influence the release of the active drug substance from the dosage forms as well as
influence their therapeutic effect at the site of action. To make the test more predictable
and clinically relevant it is essential to incorporate at least some or most of these factors
into an in vitro release test. Inclusion of these parameters can also help the researcher
in studying how a minor change in one of the parameters affects a) the other
parameters and b) the overall release of the drug from the dosage form for future
formulation changes.

Similar to IR oral dosage forms application of biorelevance in release testing of non-oral
dosage forms would ensure that the release test data is clinically meaningful and also
predictive for detection of changes in the post approval drug product. For complex nonoral dosage forms designing of the in vitro release test and selection/modification of the
appropriate apparatus requires careful research to prevent addition of unrequired layers
of complexity to the design space. However, the long-term predictive capabilities of
such

“in

vitro

release

test”

far

outweigh

the

initial

design

inconvenience.

Dissolution/release is a test model where a delicate balance needs to be established
between the lure of simulation of physiological variables as opposed to making the test
simple and more reproducible. Introduction of too many design variables in the design
space with the intention of focusing the test towards biorelevance can also cause the
introduction of overly complex and non-predictive factors. A very simple biorelevant test
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maybe rejected on the premise, that it does not provide sufficient discriminatory
capability towards crucial process parameters. The paradox thus is, although addition of
more biorelevant parameters makes the test clinically meaningful; at the same time
addition of complex physiological parameters and their interplay might make the release
test less reproducible. It is essential that ultimately the in vitro release test is an optimal
predictor of the beginning phase (e.g. burst release phase), middle and end phase of
the in vivo release profile.

However, unlike oral dosage forms where a single standardized USP method or
apparatus can be used for dissolution testing of a class of compounds, for complex nonoral dosage forms the apparatus and the method used for testing release often are
required to be adapted. Both the release testing apparatus and method parameters
have to be selected or modified according to crucial in vivo parameters to design a
biorelevant reproducible and predictable in vitro release test.

1.1.5 Currently available in vitro models for release testing of
implants
The current standardized tests offered by the United States Pharmacopeia (USP)
though suitable for oral immediate release (IR) products do not address the specific
needs of designing a biorelevant or biomimetic study design for ‘novel’ dosage forms.
Having a biorelevant model to predict or relate to the pharmacokinetics of locally and
systemically delivered controlled release biotherapeutic would help establish clinical
pertinence. Depending upon the development level of the model it could possibly also
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offer valuable insights towards the discriminatory capability of various process variables
within specific design space. Currently, there are no regulatory standards for the release
testing of implants. The United States Pharmacopeia (USP) currently offers in vitro
release testing methods (seven apparatuses - USP I to VII) that may not be suitable for
implant products e.g. INFUSE® Bone Graft. These apparatuses are not standardized for
parenterals such as implants, microspheres. The tests do not allow simulation of the
unique physiological environment(s) to which the product is exposed and hence may
not be good predictors of the in vivo performance (Bhardwaj and Burgess, 2010;
Siewert et al., 2003). It is beneficial to the researcher to ascertain the applicability of the
USP model before applying to the release tests. The complex physiological positioning
of implant based dosage forms causes a lack of information regarding the consistency
of the design space criteria and variables. This has prompted the FDA to exercise
caution in establishing regulatory guidelines for the dissolution/release testing of such
“novel” dosage forms. Currently, the most common approaches for in vitro release
testing of parenterals and implants are: sample and separate methodology, flowthrough cell (USP-IV), and modified USP-IV such as dialysis methods (Bhardwaj and
Burgess, 2010). Hybrid methods of flow-through and dialysis are also in use by some
labs; however, none of these methods have been standardized for parenteral products
(Xu et al., 2012).

1.1.5.1 Sample and separate methodology
Sample and separate is currently the most popular method for in vitro release testing of
implants due to its ease of use (D'Souza and DeLuca, 2006). The method entails a
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simple suspension of the dosage form in a certain amount of media to allow the
maintenance of sink conditions. Sampling occurs at different time intervals to best
capture the release profile. Generally, the burst release phase (specially applicable in
case of polymer based scaffolds where release of drugs due to diffusion might occur),
the middle and the end phase (>80% release) needs to be captured. Samples collected
at each time point are analyzed to determine the amount of drug released. This is
followed by either entire media replacement or the amount sampled at each time point.
Sample and separate experiments should be adjusted according to the volume of media
required for sink conditions especially in case of parenteral products like implant and
microspheres and are not required to be performed in large volumes of media as in
USP apparatus 2.
Advantages of sample and separate methodology: Agitation or stirring can also be
included as a parameter in sample and separate experiments to increase release and
affect the in vitro release profile and achieve a good In Vitro In Vivo Correlation (IVIVC).
Sample and separate experiments entail an adjustment of the various factors such as
agitation, sink conditions, sampling volume and sampling frequency. The method is
useful in establishing experimental baselines such as checking the performance of the
product for inter lab variability, in determining the most optimized handling conditions for
complex dosage forms such as microspheres, liposomes or protein based therapeutics.
The method also helps in investigation of the interaction of the dosage form with the
release/dissolution media and its stability in the media.

Once the baseline and

boundary conditions for the release test are known to the researcher, (media selection,
drug stability boundaries of time and solubility, sampling volumes and media
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replacement with sampling at each time point) a more complex, predictable and
physiologically biorelevant release or dissolution apparatus can be selected. Changes
can then be made to the flow rate, container material, and incorporation of physiological
vital parameters that are associated with release.
Disadvantages of this method are: the simulation of crucial in vivo parameters affecting
the dosage form is very limited with this technique. It lacks the vessel hydrodynamics
and functional modules to simulate biorelevant parameters affecting the dosage form.
The lack of defined hydrodynamics might also cause uneven distribution of the drug
molecule in the media, thereby giving rise to variability between experiments. Dosage
form aggregation might also be observed due to the lack of appropriate media flow. In
addition there is no physical separation of the dosage form from the media which maybe
required for certain special carrier scaffolds like collagen, hydroxyapatite particles,
microspheres and liposomes. This makes sampling at each time point difficult.

1.1.5.2 USP-IV Flow through cell methodology
Continuous flow release methods such as USP-IV flow through cell have been used as
an industry standard for in vitro release testing of extended release dosage forms
(Fotaki et al., 2009; Thomas, 2016; Xu et al., 2012; Zolnik et al., 2005). A USP-IV flow
through experimental set up comprises of various components: glass cells constituting
the USP-IV apparatus, small glass beads to position the dosage form, membranes or a
large glass bead of diameter 5mm to prevent the flow of the glass beads and dosage
form positioned on top of the cell inlet tubing, a pump for driving the flow of the media,
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tubings, a reservoir to maintain sink conditions, and finally an incubator or water bath
which generally maintains the reservoir and its fluid at the required temperature (USP,
2012).
Traditional USP-IV flow through cells as described by US Pharmacopeial Convention in
Chapter <711> on dissolution are generally of two types: a) 26mm i.d. cell and b) 12mm
i.d. cell. They are called as the large cell (fluid volume 19mL) and small cell (fluid
volume 8mL) respectively (USP, 2012). Each has a tablet holder for tablet and
capsules. The tubing connecting the cell to the pump driving the media should be as
small as possible in length. Care should also be taken to select tubing of inert material
so that the drug substance e.g. protein has minimal adsorption and chemical interaction
with the material of the tubing. Media is generally forced up the inlet and into the flow
through cell. The dosage form e.g. tablet or capsule in case of immediate release
dosage form and implants in case of non-oral dosage forms is placed perpendicular to
the path of the flow. The addition of small glass beads helps in making the flow laminar
and not turbulent (Burgess and Wright, 2012). Either half of the cells are held together
by two O-rings and a steel clamp. An attempt must be made to physically position the
pump driving the media on a different surface from where the USP-IV apparatus is
placed. This would protect the cell from any unplanned agitations (such as vibrations
due to the pump).

Closed or Open Loop flow of media: A flow through cell set up can be configured in a
closed or open loop system. In an open loop system fresh dissolution or release media
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is continuously pumped into the flow through cell via the reservoir. In a closed loop
system the media volume is kept constant and the same media is circulated in a loop
through the dosage form. The volume of media to be circulated is calculated based on
the net diameter of the flow through cell chosen, the tubing connections and the sink
conditions for the drug substance. Generally sink conditions are chosen as three times
the solubility of the drug substance in the media as defined by the USP (Burgess and
Wright, 2012; US Pharmacopeia, 2011b). An open loop configuration is generally
selected for dissolution studies involving poorly soluble drugs whereas closed loop is
selected for drugs with good solubility.
Advantages of using the USP-IV apparatus are evaporative losses are minimal with this
apparatus and the hydrodynamics of the apparatus have been well studied and defined.
Adjustments to sample immobilization (i.e. glass beads for positioning), flow rate, and
media recycling can also be made as necessary.
Disadvantages of this method are filter blocking and clogging due to disintegration of
the dosage form caused by flow. This is observed particularly when used with polymer
materials such as PLGA and collagen carrier scaffolds, which lose material from the
surface over an extended period of time. The blocking of the filter material by damaged
formulation components causes excess backpressure since the flow of the media in
USP-IV is through the filter membrane. This leads to disruption of the experimental set
up for extended release dosage form studies and greater variability in measurements.
Drug or protein adsorption on tubing or glass beads and specifically on the glass flow
through cell (for protein biotherapeutics) leads to loss of the measured drug substance
or API and again enhanced variability. Another crucial factor is the minimal volume of
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the flow through cell cannot be decreased beyond a certain value. This is important in
case of implants and some parenteral which require minimal media volume to mimic
physiological biorelevant conditions.

1.1.5.3 Dialysis methodology
Dialysis is an important modification often incorporated in many release test study
designs (Bhardwaj and Burgess, 2010). Dialysis methods are also used where the
sample is required to be segregated from the bulk media by placement in a dialysis sac
(D’Souza and DeLuca, 2005). This helps simulate a permeation barrier. The dialysis sac
can be an artificially available applied membrane with requisite molecular weight cut off
(MWCO). The sac allows the drug to diffuse out and into the media for sampling.
Dialysis techniques can be performed where the drug is placed in the sac and sampling
takes place in the media or reverse dialysis where the drug is placed outside the sac
and sampling takes place inside the sac. Many a times in vitro release profiles obtained
in these cases do not correlate with the in vivo performance, which may be derived from
lack of agitation and subsequent aggregation of dosage forms like microspheres inside
the dialysis sacs (Burgess et al., 2002b). Frequently, one or a combination of these
methods (i.e. sample and separate and dialysis or USP-IV modified with dialysis
adapters) are used by researchers in designing biorelevant release tests for unique
dosage forms depending on their needs (Bhardwaj and Burgess, 2010). It is therefore
critical to choose the most relevant apparatus for release testing of complex dosage
forms. Efforts have been underway to develop modified, biorelevant in vitro release
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testing approaches for accurate release characterization of novel products (Delvadia et
al., 2012; Iyer et al., 2007a; Iyer et al., 2006).

1.1.6 Evaluation of in vitro in vivo relationships
Biorelevant ‘real time release tests’ can be of particular significance during scale up and
post approval stages of a drug (SUPAC) : a) for monitoring and predicting the outcome
during minor formulation changes, b) as a quality control test during the commercial
manufacturing process for monitoring of ‘batch to batch variability’ (Brown et al., 2011;
Siewert et al., 2003) and c) can essentially function as a discriminatory
dissolution/release model between different formulation variants. The primary
expectation from a well-developed and validated biorelevant test method would be the
ability to predict in terms of release or dissolution, how any intrinsic variation in any of
the process variables of commercial manufacturing conditions would affect changes in
the release profile of the drug. At the same time the principal impetus behind developing
such tests are also to: 1) minimize time 2) cost and 3) the significant reduction of animal
clinical trials. Over the past few decades, applying biorelevance in release and
dissolution testing has proven to be a powerful tool towards providing In Vitro In Vivo
Relationships/Correlation (IVIVR/IVIVC). Such predictive relationships obtained from
IVIVR/IVIVC can be effectively translated to clinically meaningful specifications and
contribute towards relevant information pertaining to the performance of the drug.
However, often times since such complex dosage form might have only one kind of
formulation and reaching a Level A correlation or meeting the levels of correlation as
that for an immediate release dosage form might be difficult. Due to the complexity in
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physiological positioning of parenterals, implants, injectable liposomes based dosage
forms there is lack of information regarding the consistency of the design space criteria
and variables. This has prompted the FDA to exercise caution in establishing regulatory
guidelines for the dissolution/release testing of such complex non-oral dosage forms.
There is sufficient evidence for a significant need to develop adaptable in vitro model
systems that can be predictive of in vivo formulation release of complex non- oral
dosage forms.

1.1.7 IVIVC/IVIVR/IVR
1.1.7.1 IVIVC for Parenteral/ IVIVR
In Vitro In Vivo Correlations serve as essential tools in guiding and speeding up the
process of drug development by providing a scalable and predictive relationship. A
successful IVIVC helps in predicting the in vivo performance of the drug in a time
efficient way with the help of in vitro dissolution profiles. For obtaining a predictive IVIVC
it is essential that a clinically biorelevant predictive release method be developed. Since
dissolution or release tests are predictive, repeatable and set up in a controlled
environment in the lab they can be easily used to save time and predict in vivo release
of either different formulations or minor changes to a formulation.

There are four levels of IVIVC: Level A, B, C and D as described by the FDA guidelines
for extended release dosage forms (FDA Rockville, 1997). A level A correlation is a
point to point correlation between in vitro dissolution data and in vivo absorption data. It
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represents a relationship between in vivo fraction of drug absorbed and in vitro fraction
of drug dissolved. The fraction of drug absorbed in vivo is obtained from the in vivo
pharmacokinetic profile using deconvolution and transformation of data on drug plasma
profiles. The transformation of data is carried out using methods such as Wagner
Nelson or Loo Riegelmann. Generally a linear relationship is expected of a Level A
correlation and is most commonly used to establish bioequivalence and biowaivers. A
level B correlation demonstrates a relationship between mean in vitro dissolution time
(MDT
vitro

in vitro)

and mean in vivo residence time (MRT

in vivo).

Since a MRT

in vivo

and MDT

in

is based on the principle of statistical moment analysis and can be obtained from a

number of plasma in vivo and in vitro dissolution/release profiles, it is not a point to point
correlation. Level C correlation specifies a relationship between a dissolution profile
parameter and a in vivo pharmacokinetic parameter such as AUC, Cmax or Tmax. The
in vitro dissolution parameter can be a parameter such as time taken for 50% of the
dissolution to occur T50% or percent dissolved in 4hrs (FDA Rockville, 1997). As is
evident it is a single point correlation and not as predictive as a level A point to pint
correlation. A level D correlation is the final stage of correlation and is a rank order
correlation. Since level A IVIVC is the highest degree of correlation it is often the
targeted standard. An IVIVC is validated by measuring the percentage prediction error
(%PE) for its ability in predicting AUC, Cmax and other relevant pharmacokinetic factors.
The industry standard is for the % PE to be within ± 10% (FDA Rockville, 1997).

In many cases such as immediate release dosage forms where dissolution is rapid it is
observed that the in vitro dissolution progresses at a much rapid rate than in vivo
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absorption. In such release/dissolution profiles the in vivo absorption lags behind the in
vitro dissolution and makes achieving a linear correlation difficult. In such studies either
scaling can be used and a predictive ‘relationship’ can be determined between the in
vitro and in vivo profile (Polli, 2000). The primary aim of developing such an in vitro in
vivo relationship (IVIVR) like IVIVC, is to determine a predictive or/and scalable
relationship between in vivo absorption profile and in vitro dissolution profile.
Immediate release dosage forms require much shorter time in vivo for their release.
However, in case of parenteral or extended release parenteral like INFUSE® Bone Graft
this time is further extended. Thus, an in vitro dissolution or release test, which, is
accelerated, can be very helpful in speeding up the drug development process. In case
of parenteral an IVIVR might not be always possible. Achieving particularly a Level A,
Level B, Level C correlation might not be possible. In such a case scenario an IVIVR
can act as a good predictor of the in vivo profile.

1.1.7.2 Challenges with developing IVIVC/IVIVR for complex dosage
forms
Although many studies and IVIVC have been established in the past for immediate
release dosage forms and extended release oral dosage forms, application of
IVIVC/IVIVR to complex dosage forms such as parenterals (liposomes, nanoparticles,
carrier based biodegradable implants, ocular inserts and drug eluting stents) have been
limited in literature (Shen and Burgess, 2015). Complex dosage forms give rise to
multiple factors that offer hindrance to a conventional IVIVC or IVIVR.
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First, complex or special dosage forms such as INFUSE® Bone graft, ocular implants
are placed in complex physiological environment such as maxillary sinus cavity and
ophthalmic chambers of the eye. These regions generally vary greatly in their
vascularity, fluid viscosity, fluid pressure, and organic and inorganic composition of
fluids. This gives rise to major changes in the drug release, diffusion, distribution and
clearance processes. In many situations such as INFUSE® Bone graft the systemic
clearance of the drug substance rhBMP-2 protein is high. The t1/2 of rhBMP-2 in rats
and non human primates is 16 minutes and 6.7 minutes respectively (FDA Rockville,
2014). In such scenarios getting precise plasma concentration pharmacokinetic profile
is difficult because of rapid systemic clearance and difficulty in vivo in accessing the
complex tissue chambers. In case of INFUSE® Bone graft the performance efficiency of
the dosage form has been measured by the retention of rhBMP-2 in the carrier scaffold
at the local site rather than in the systemic circulation. Local retention has been in turn
correlated in multiple studies with bone growth in terms of height and density and
compared to autologous bones (Boyne et al., 2005; McKay et al., 2007). Therefore, in
such carrier based complex dosage forms retention in the scaffold can be the primary
indicator of bone healing and regeneration. Development of an IVIVR or establishing an
In Vitro Relationship (IVR) in such a case would be more clinically relevant, if it would
enable to establish a predictive relationship between in vitro release and in vivo
retention. Such a relationship then would be an indicator of how minor changes in
formulation, stability, manufacturing would affect the local retention and hence
performance of the dosage forms.
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Secondly, especially in case of controlled release dosage forms a multiphasic release is
observed. Dosage forms such as liposomes, carrier based scaffolds (INFUSE® Bone
graft) show an initial phase of burst release in vivo followed by an exponential steady
release and finally a lag phase in release (Monkhouse et al., 2003). The initial burst
release phase can be due to diffusion controlled processes or presence of enzymes and
proteins in the plasma such as collagenases which speed up the initial release. Also an
externally placed implant in the physiological environment maybe subjected to local
effects of cells as a part of the inflammatory stage, which might attack and partly clear
off the carrier scaffold or polymer resulting in a burst release phase. Many times
degradation products of the polymer such as PLGA, or scaffold such as collagen are
known to accumulate in the tissue healing microenvironment and may increase or
decrease the pH of the surrounding tissue fluid thereby affecting release.

Although biorelevant media can be best picked for biorelevant release studies
depending upon its inorganic ion concentration, pH and osmolality mimicking exact
variability of the complex plasma protein concentrations is difficult. In addition to the
variability, introduction of serum or plasma proteins into the in vitro release testing
methodology gives rise to problem with the analytical methodology due to interference
of these components of the plasma, and makes such release tests less predictable.
Hence, it is better to use biorelevant media components, which have minimal to no
interference

in

the

quantitation

and

analytical

pharmaceutical ingredient (API).
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Lastly, the biorelevant apparatus and the analytical methodology can themselves pose
difficulties for characterizing release and developing a predictive release method. To
develop a clinically relevant release/dissolution method it is essential to add parameters
to the release test that mimic the actual physiological environment without making the
test too complex to be performed in a lab setting or compromising the ability of the test
to be reproducible. Addition of such parameters help in predicting changes in the
behavior of the dosage form, with, changes in these biorelevant parameters. The
analytical test methodology can also have an impact on the development of the release
test. A stability indicating analytical method capable of detecting degradation products in
the in vivo physiological environment and also for release media should be used to
calculate of the amount of drug released.

1.2 DESCRIPTION OF THE MODEL DOSAGE FORM: INFUSE®
BONE GRAFT
INFUSE® Bone Graft is an osteoinductive and osteointegrating implant based dosage
form for de novo regeneration of biologic bone. It has been used in many parallel
indications such as spinal fusion in patients with degenerative disc disease, healing of
tibial shaft fractures and in sinus lift/sinus augmentation surgeries (FDA Rockville, 2001,
2014; Medtronic, 2011)(FDA Rockville, 2001; Medtronic, 2011). Figure 1-1 is a pictorial
representation of INFUSE® Bone Graft being used in sinus lift surgery (Medtronic,
2011).
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Figure 1-1. A pictorial representation of application of Infuse Bone Graft during sinus lift
/ augmentation surgery
(Medtronic, 2011)
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INFUSE® is composed of two major components: 1) recombinant human Bone
Morphogenetic Protein-2 (rhBMP-2) which is the functional bone regenerating protein at
a concentration of 1.5mg/mL and 2) Absorbable Collagen Sponge (ACS), the carrier
scaffold for the protein. ACS is a bovine Type I collagen cross-linked by formaldehyde
and sterilized by ethylene oxide to increase its retention capability for rhBMP-2. ACS
serves two primary functions: 1) It acts as a carrier for the rhBMP-2 to enhance its
retention at the local targeted trauma/healing site and 2) It acts as an adjuvant scaffold
for the invading osteoprogenitor cells to act as a supportive matrix for initiating the
process of bone growth.

1.2.1 Structural and Physicochemical properties of rhBMP-2
1.2.1.1 Structural properties of rhBMP-2:
Bone Morphogenetic Protein-2 (BMP-2) is a member of the Transforming Growth
Factor- β (TGF-β) family of signaling molecules (Clark and Coker, 1998). TGF-β are
multifunctional cytokines that regulate inflammation and immunity. They are also vital to
growth, cellular proliferation and differentiation during both the adult and embryonic
phases (Clark and Coker, 1998). BMP-2 is initially synthesized as a 453 amino acid
proprotein. The signal peptide and the propeptide regions of this proprotein are then
cleaved to give a 114-residue monomer (Porter et al., 2004; Scheufler et al., 1999). The
monomers further form dimers by a disulfide linkage. Since rhBMP-2 in INFUSE® Bone
graft is synthesized in the Chinese Hamster Ovary (CHO) mammalian cell line, it is also
glycosylated and folded into a homodimer within the cell itself. Unlike general globular
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proteins the TGF- β family lacks a stabilizing hydrophobic core. As a result the protein
acquires stability by a distinct cysteine knot structure and by dimerization. The cysteine
knots are formed within a monomer between 6 cysteine residues: Cys296->Cys361;
Cys325->Cys393; Cys329->Cys395. The dimerization occurs by a covalently linked
disulfide bond formed between Cys360 residues of the two single units. This results in a
hydrophobic like core and provides the required stability to the protein. Although as a
monomer the hydrophobicity of BMP-2 is extremely low (calculated hydropathy score: .56 (Gasteiger E., 2005)) the dimerization renders BMP-2 with a) sufficient
hydrophobicity to be eluted by reverse phase chromatography column and b) also leads
to its aggregation under unfavorable conditions of pH, temperature and

storage

(Scheufler et al., 1999)] . The net dimensions of the homodimer are 70 Å × 35 Å × 30 Å
(Scheufler et al., 1999).
The actual processed peptide is from Threonine266 or Glutamine283- 396 arginine
residues depending on the N terminal cellular processing. The protein has a ‘NST’ is the
single N-glycosylation site of the protein beginning at Aspargine338 (Bernstein et al.,
1977; Kouranov et al., 2006)
.

1.2.1.2 Physicochemical properties of rhBMP-2:
The physicochemical properties of rhBMP-2 were calculated using Expasy- ProtParam
tool available online (Gasteiger E., 2005). This step helps establish a basic idea about
the hydrophobicity and theoretical calculated pI of the protein (Scheufler et al., 1999).
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ProtParam helps in computing various physicochemical parameters for proteins
(Gasteiger E., 2005). These are deduced based on the protein sequence and modeling
of this sequence in three dimension. The software generates a Grand Average of
Hydropathy (GRAVY) value for a protein or peptide. The hydropathy scores give a basic
idea about the hydrophobicity of the protein. The GRAVY value for a protein is
calculated by summing the hydropathy values of each amino acid divided by the net
total number of residues in the molecule. Since chromatographic methods basically
work on the mechanism of partitioning of the analyte between the mobile and stationary
phases knowledge about hydrophobicity of the protein molecule can be useful
especially in RPLC in providing ideas about the kind of column that must be selected,
for the development of an RPLC method. The calculated hydropathy score/GRAVY for
rhBMP-2 was: - 0.56. This meant that the protein had comparatively low hydrophobicity
(hence the C3 column selected in the development of the method). The theoretical pI
calculated by the software was 8.92. Knowledge of the pI of the protein helps in
determining what net charge the protein will carry at the sample injection pH and the
mobile phase pH. This helps in approximately estimating the degree of hydrophobicity
of the analyte molecule. In conclusion, all these factors added together such as: a) the
dimensions of the protein (essential for determining the pore size of the column); b)
hydropathy scores (for selecting the type of column e.g.C3-C18 or column functional
group extensions); c) protein pI (for determining the pH of the eluting mobile phase and
sample injection pH at which the protein moiety will be most stable) help in getting an
optimal analyte response during chromatographic method development and validation.
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1.2.2 Factors affecting rhBMP-2 release from its carrier
biopolymer
1.2.2.1 rhBMP-2 release from ACS:
Recombinant human Bone Morphogenetic Protein-2 (rhBMP-2) is a growth factor that
helps in bone growth and differentiation. The delivery of rhBMP-2 for osteoinduction
requires a prolonged retention, at supraphysiological doses, at the site of action. For
this purpose the best strategy for rhBMP-2 delivery is using a carrier scaffold that can
retain the protein at the implant site. A distinct positive correlation has been found
between the retention of rhBMP-2 at the local site of action and osteoinduction (Uludag
et al., 2001). An ideal carrier for rhBMP-2 needs to strike a delicate balance between:
biodegradability and controlled in vivo degradation. The 3D porous structure for cellular
adherence and penetration by osteoprogenitor cells, needs to be malleable enough to
be packaged into wound healing sites. At the same time, it has to be tensile enough to
withstand a) the force of packaging b) not collapse and c) retain the incorporated
rhBMP-2 under masticatory pressure for controlled release over several days. A few of
the required attributes in a carrier suited for rhBMP-2 delivery have been listed in Table
1-1. Collagen scaffolds i.e Absorbable Collagen Sponge (ACS) used in INFUSE® Bone
graft meets almost all the requirements mentioned in Table 1-1 to a considerable extent
(Friess, 1998). Collagen sponges have been used widely in clinical settings as
hemostatic agents. The mechanism of release of rhBMP-2 from ACS is thus a complex
balance of two principal characteristics: a) binding or retention of rhBMP-2 in ACS and
b) ACS biodegradation at the requisite rate.
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1.2.2.2 Mechanism of rhBMP-2 release from ACS:
The mechanism of rhBMP-2 retention and release from the ACS was primarily
elucidated by Freiss et. al (Uludag et al., 1999b). They studied the effects of in vitro
sponge characteristics, protein pI and retention on in vivo rhBMP-2 pharmacokinetics
(Friess et al., 1999a; Uludag et al., 1999b). rhBMP-2 has an isoelectrical point of ~8.5.
Thus, it carries a net positive charge at physiological pH. The binding of rhBMP-2 on the
collagen scaffold is mostly by non-covalent interactions like electrostatic and
hydrophobic interactions between the rhBMP-2 protein and collagen residues. However,
changes in various physicochemical and biological properties of the collagen sponge
and the rhBMP-2 solution can influence the above interactions. Collagen scaffolds
generally show a biphasic release profile- a) the initial burst release phase and b)
sustained release for days to a month (Friess et al., 1999b; Geiger et al., 2003). The
various significant factors that had a major effect on the retention and release of rhBMP2 from ACS were: pH, ACS mass, anion concentration and crosslinking and sterilization
of the ACS. Their effects on the mechanism of rhBMP-2 release from and retention in
ACS have been discussed in detail below:
Effect of pH changes: Equilibrium binding studies of rhBMP-2 and ACS were conducted
(Friess et al., 1999b). The ACS was initially soaked in excess rhBMP-2 solutions at
varying pH and incubated. After 24-48 hr the amount of rhBMP-2 bound to the ACS
was found as the percentage incorporated (%Inc). It was observed that by increasing
the pH
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Table 1-1. Critical attributes of an ideal rhBMP-2 carrier
(This table has been modified from references (Burg et al., 2000; Geiger et al., 2003b))
1. Permits cellular infiltration, cellular adherence and
vascularization – Acts as a supportive matrix.
2. Sufficient binding affinity to rhBMP-2.
3. Degrades into biocompatible components – biodegradable.
4. Low immunogenicity and – biocompatibility
5.Can be packaged into a physiological trauma site – malleable.
6. Can withstand compression without structural collapse- tensile.
7.Controlled release of rhBMP-2 during the period of bone
healing.
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of the rhBMP-2 solution from pH of 3 to a pH 6.5 the mg/mg of rhBMP-2 binding to ACS
equilibrium binding increased from less than 0.01 mg/mg to 0.18 mg/mg. This binding
and retention mechanism of rhBMP-2 with ACS was explained by the difference in their
isoelectrical points. The alkali treated collagen has cleaved negatively charged
aspargine and glutamine residues, which imparts a net pI of 5.1 to collagen. The pI of
rhBMP-2 is between 8~9. Thus, rhBMP-2 carries a net positive charge at the abovementioned pH of 3-6.5. At the same time with an increase in pH beyond the pI of 5.1 for
collagen the negative charge on the molecule increases. The result is a net increase in
binding between the two protein molecules as we move from a pH of 3-6.5.

ACS mass was also found to have a significant effect on rhBMP-2 protein binding
(Friess et al., 1999b). It was observed that with an increase in ACS mass the reduction
in protein loss due to mechanical pressure during implantation could be minimized. This
was due to the maximization of rhBMP-2 incorporated in ACS at a higher mass. The
increase in ACS mass facilitated greater availability of rhBMP-2 binding sites and hence
enhanced retention of the rhBMP-2 in the scaffold.

Anion concentration was also found to have an effect on rhBMP-2 retention and release
mechanism from the ACS (Friess et al., 1999b). When ACS is equilibrated with
increasing concentrations of chloride ion ranging from 5mM to 15mM enhanced
retention occurs from 50% at pH 5.1 to approx. 80%. However, an anionic increase
above 20mM for sodium chloride ions leads to rhBMP-2 precipitation.
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Crosslinking and Sterilization also affected the rhBMP-2 incorporation and release from
ACS (Friess et al., 1999a). Crosslinking was carried out with formaldehyde and
sterilization of the sponge with ethylene oxide. Crosslinking led to a stronger interaction
within the collagen mesh and made it more tensile. Sterilization by ethylene oxide
caused a reduction in the denaturation temperature of ACS and made it more sensitive
to collagenase (which at a controlled rate is required for biodegradation of the scaffold)
(Uludag et al., 2001). The non-crosslinked/non-sterile, crosslinked/non-sterile and
crosslinked/sterile ACS were implanted in a rat ectopic model with radiolabelled
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rhBMP-2. The in vivo release kinetics was studied by sacrificing two positive controls (4
implants) and two negative controls at each time point. The implants were excised and
the total radioactive counts were calculated as the percentage of rhBMP-2 retained. The
in-vivo release kinetics was elucidated non-compartmentally and by a bi-exponential
model. The t1/2a and the t1/2b of the two phases of the model were 10min and 89hr. It
was observed that crosslinked/sterile sponges gave the highest mean residence time
for t1/2b in vivo of 89hr (Uludag et al., 1999b).

1.2.3 Mechanism of action of INFUSE® Bone Graft
rhBMP-2 acts as a chemotactic agent for attracting mesenchymal stem cells and
osteoblasts, to the local application site by initiating chemotactic migration of cells
(Ebara and Nakayama, 2002; Li and Wozney, 2001) . Once the required pluripotent
cells have migrated to the site rhBMP-2 binds to the receptors on their surface and
causes their differentiation into bone generating cells-osteoblasts. The advantage of
using rhBMP-2 on a biodegradable scaffold in comparison to a patient’s autologous
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bone is there is no inflammation and secondary complications like pain and healing
delays associated with the bone harvested secondary site. INFUSE® Bone Graft
induced bone when compared to autologous bone showed that the density of the newly
formed bone was higher than that of autologous bone and it functioned and responded
normally. Revascularization and consolidation of the new bone occurred as would occur
for autologous bone which, is currently the gold standard for bone regeneration.

However, rhBMP-2 has some side effects, since it is a member of the TGF-β family of
inflammatory molecules it cannot be used in patients with tumor/malignancy or those
suffering from active inflammation at the trauma site. INFUSE® Bone Graft shows a
distinct burst release phase during which about 25% of the molecule is released from
the scaffold which might adversely affect the trauma site that might already be
experiencing inflammation. Nor can rhBMP-2 be used in pregnant women since BMP-2
is actively involved during the stages of fetal cell differentiation (Chen et al., 1997). This
limits the use of rhBMP-2 due to potential risks and hence the need for a better
understanding of the controlled release of rhBMP-2 from its scaffold and exploration of
its elusive local pharmacokinetics.

1.2.4 INFUSE® Bone Graft as a model test implant for
biorelevance in vitro release studies
While designing our biorelevant in vitro system we decided to select INFUSE® Bone
Graft as a model implant as it would be a classic test-bed considering 1) it’s wide yet
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novel usage in orthopedic trauma and healing surgeries for the regeneration of bone
and 2) In spite of the predictable clinical performance of INFUSE® Bone graft rhBMP-2
has been associated with many safety and efficacy issues due to its less studied local
release pharmacokinetics from the ACS, which might have unprecedented effects in
patients. There is a tremendous scope to study how different formulations involving
different carrier matrices might affect the release kinetics of rhBMP-2. Controlling the
initial burst release phase would significantly affect the safety and efficacy of the
formulation. This model biorelevant in vitro system when developed can be translatable
and applied to study the local and systemic release of other protein formulations.
Although the release of rhBMP-2 from ACS using radiolabelled
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I has been studied

(Uludag et al., 1999a), this research will provide a means of studying and quantifying
the release in vitro in a release study system using a label free methodology of rhBMP-2
detection. Application of our developed and validated High Performance Liquid
Chromatography (HPLC)-UV method would limit destructive sampling of the implant at
each sampling time point. This biorelevant in vitro model will help in predicting and
relating in vivo orthobiologic delivery (IVR) of the only marketed bone tissue
regenerating molecule rhBMP-2.

1.2.5 Model Design and innovation
The engineered biorelevant in vitro model will be a novel approach towards testing an
intra-osseous implant at a complex physiological position involving low vascularity and a
distinct microenvironment. In addition to the model system having multiple chambers for
testing local release, the model also facilitates physical separation of the carrier scaffold
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from the release media if required. The novel biorelevant in vitro model design helped in
studying the effects of flow directionality on the release of rhBMP-2 from ACS.

According to the guidelines and specifications provided by the USP chapter <1092> the
release test design was performed in a step-by-step modular approach for this research
investigation. Chapter 3 of the thesis describes the development and validation of a
stability indicating HPLC-UV method for the quantitation of rhBMP-2 (the drug
substance) in the release medium. Chapter 4 of the thesis introduces the use of
conventional methodologies such as sample and separate followed by a USP methodflow through cell and finally leads to the development of an in-house release model
called Biorelevant In Vitro Drug Release (BIVDR) model and its study for discriminating
between formulations. The in vitro in vivo relationship was evaluated with the help of
Sprague Dawley rat cumulative release profiles and a predictive relationship was
established. The difference (f1) and similarity (f2) factors were calculated to investigate
the discriminatory capability of the developed release study design.
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CHAPTER 2

2 DISSERTATION OBJECTIVES

In vitro dissolution/release testing is an essential tool for performance verification of a
dosage form in pre-clinical and clinical stages. These tests help us in development and
evaluation of an in vitro in vivo relationship/correlation (IVIVR/IVIVC). IVIVRs help
establish a predictive clinical relevance of the in vitro release test. With the development
in the fields of biotherapeutic modalities the number and diversity of ‘novel’ non-oral
dosage forms placed in complex physiological tissues have also taken a leap forward
e.g. ocular implants, drug eluting stents, sinus augmentation implants, spinal implants
(McKay et al., 2007; Seidlitz et al., 2011a; Wong et al., 2001). The primary objective of
this research is to develop a biorelevant in vitro release test model for a ‘novel’ non-oral
dosage form INFUSE® Bone Graft. The model dosage form is unique and challenging in
its study because of three central aspects:
i)

The API is a recombinant biotherapeutic bone regenerating protein modality
(rhBMP-2) of molecular weight 32kDa, thereby posing challenges in its
stability in dissolution/release media and analytical method development.
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ii)

The drug substance is carried in a biodegradable carrier scaffold (absorbable
collagen sponge), thereby making its release mechanism complex and
‘multiphasic’.

iii)

The efficiency of the dosage form is dependent on its retention and release
at the local site of action (inflammatory physiological conditions) instead of in
the

systemic

circulation,

thereby

posing

challenges

in

acquiring

representative pharmacokinetic data and establishment of an in vitro in vivo
relationship.

With these challenges in perspective, the first objective of the research was to develop
a stability-indicating high performance liquid chromatography (HPLC) method. The
method would support the analysis of the recombinant human bone morphogenetic
protein-2 (rhBMP-2) in the selected biorelevant release media- modified Hanks’
balanced salts solution (HBSS). Stability analysis of the drug substance rhBMP-2 was
explored in the media over selected ranges of temperature and time. Forced
degradation studies during the development of the method helped to verify if the method
could detect presence of degradant peaks. This helped ascertain if the analytical test
methodology could detect interferences and degradants during the in vitro release test
study design. The method was also validated to ensure precision and accuracy of the
results obtained during the in vitro release test.

The second objective of the study was to apply conventional in vitro dissolution / release
methods like sample and separate and USP-IV flow through cell methodology to the
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model implant. A comparative in vitro cumulative release profile of the dosage form was
developed and compared to the in vivo cumulative release profile. The components of
the in vitro release apparatus that led to incomplete and non-representative cumulative
release profiles were analyzed and a biorelevant in vitro drug release (BIVDR) model
was finally designed and developed to meet the requirements of the novel implant
based dosage form.

The third objective of the research was to design and develop the chambered BIVDR
model to simulate a physiological low volume fluid surrounding area meeting the
requisite sink conditions for the implant. The BIVDR model was developed in a
sequential modular approach to optimize the model components for low protein
adsorption and maximal recovery. The model was applied to the model implant
INFUSE® Bone graft and a cumulative in vitro release profile was obtained for >80%
release of the drug substance.

The fourth and final objective of the research was to explore if the in house developed
BIVDR model and release test was discriminatory between different formulations of the
drug substance (rhBMP-2) by using different carrier scaffolds. Absorbable collagen
sponge (INFUSE® Bone graft) and hydroxyapatite (Osteograf N-300) were used as the
carriers. A predictive in vitro in vivo relationship was established by using time scaling
and levy plots. Similarity (f2) and difference (f1) factors were established for the release
profiles of the two different formulations to establish if the release method was
discriminatory between formulations.
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CHAPTER 3

3 3 Development & Validation of a Stability-Indicating HPLC
Method for rhBMP-2 Protein Formulation in a Biorelevant
Release Media and Characterization of its Intact
Glycoforms using Mass Spectrometric Detection
Drawn from a manuscript submitted to J. Pharm Analysis

3.1 INTRODUCTION
Bone morphogenetic protein-2 (BMP-2) is an osteoinductive and osteointegrating
signaling molecule (Carragee et al., 2011). It is secreted in the human body as a
glycoprotein and the molecular weight of its dimer isoforms are between 26-30kDa
(Carragee et al., 2011; Friess et al., 1999b; Urist, 1965). It belongs to the Transforming
Growth Factor-β family of cytokines which are critical in cellular formation and
differentiation, predominantly during the embryonic stages (Clark and Coker, 1998).
Recombinant BMP-2 in the past decade has largely been cloned in Chinese Hamster
Ovary (CHO) cell lines. When applied as a formulation with a biodegradable scaffold at
the trauma site, it helps in bone regeneration and healing. It has been used as an
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alternative to autograft bone for spinal fusions, healing of tibial fractures and sinus lift
augmentation surgeries (Geiger et al., 2003; McKay et al., 2007; Urist, 1965). Currently,
one such FDA approved indication of recombinant human BMP-2 is INFUSE® Bone
Graft (Medtronic, Minneapolis, MN, USA). The formulation is marketed as a combination
of lyophilized powder of rhBMP-2, which has to be reconstituted with sterilized distilled
water and an absorbable collagen sponge (ACS) (FDA Rockville, 2007b). After
reconstitution at 1.5 mg/mL, the solution is distributed uniformly on the surface of the
sponge. An initial period of 15-30 min is allowed for non-covalent binding of the rhBMP2 protein to the collagen sponge. The final indication is then applied at the site of trauma
or for oral surgery by the clinician (FDA Rockville, 2007b). Bone regeneration at the
intended site (sinus lift, trauma or spinal fusion) occurs by controlled and extended
release of the rhBMP-2 protein from the biodegradable scaffold (ACS).
‘Biorelevant’ in vitro dissolution or drug release tests act as a surrogate quality control
tools for performance verification of the pharmaceutical formulation and ensures
minimal inter-batch variability (Biswas and Halquist, 2016; Brown et al., 2011). It helps
in establishing clinically relevant specifications. These release tests for ‘novel’
formulations such as implants, help in investigating the effects of physiological variables
on the release mechanism of drugs at the complex site of action. To assess and
compare the in vitro release of rhBMP-2 to the available in vivo data, we designed a
‘biorelevant’ in vitro drug release (BIVDR) model. Correlation of the in vitro data
obtained using the BIVDR model, with in vivo data will help establish an In Vitro In Vivo
Relationship (IVIVR). The in vitro studies were performed in a biorelevant release media
simulating plasma, using modified Hanks’ balanced salts solution (modified by removal
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of phenol red and sodium bicarbonate components) (Iyer et al., 2007c). In order to
analyze the rhBMP-2 release samples in biorelevant media, a reliable, precise, accurate
and stability indicating high-throughput assay method was required. Previous
measurements of rhBMP-2 relied upon enzyme-linked immunosorbent assays (ELISA).
However, the linear range for the ELISA kits would require expansive dilutions (i.e., 104
~ 106 dilution for release samples) not practically applicable to the release studies, due
to it’s limited dynamic range (62.5 - 4000 pg/mL). Given that other early analytical work
has shown the use of a reversed phase (RP) C4 resin for the extraction and purification
of the rhBMP-2 protein from CHO cell lines, growing in cell culture media (Chen et al.,
1997; Israel et al., 1992), this offers a starting point to developing an RPLC-UV method.
The objective of this chapter is to develop and validate a stability-indicating HPLC assay
method which is: a) time and cost effective, b) can be reliably used for direct analysis in
the range (0.5 -100 µg/mL) and c) the validated method must be able to quantify the
release of rhBMP-2 from ACS into the biorelevant release media. Validation of the
developed method focused on evaluations of linearity, intra-day and inter-day precision,
intra-day and inter-day accuracy, recovery, and system suitability. Effects of forced
degradation conditions have also been assessed in this work, to detect the presence of
any potential chromatographic interfering compounds in the formulation such as
excipients and biorelevant release media. Forced degradation studies involved studying
effects of acid, base, oxidation, and temperature (thermal degradation) based stress
conditions on the drug substance. Differential isoforms of rhBMP-2 in the formulation
have

also

been

investigated

using

mass

spectrometric

detection

biotransformation of them was evaluated by inducing stress conditions.
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and

the

3.2 MATERIALS AND METHODS
3.2.1 Chemicals and Reagents
INFUSE® Bone Graft components were donated by Medtronic (Minneapolis,
Minnesota). HPLC grade mobile phase components a) acetonitrile was purchased from
VWR (Radnor, PA), b) water from Fisher Scientific (Waltham, MA USA) c) trifluoro
acetic acid was purchased from EMD Millipore (Massachusetts). Modified Hanks’
Balanced Salt Solution (without phenol red and sodium bicarbonate) (Iyer et al., 2007c)
and 4-(2-hydroxy ethyl) piperazine-1-ethanesulfonic acid (HEPES buffer, 1 mM) were
purchased from Sigma-Aldrich (St. Louis, MO). Polyethersulfone syringe filters (0.45
µm, Whatman) that were used to filter the prepared modified HBSS were purchased
from VWR (Radnor, PA). Protein biocompatible inserts for use in HPLC of rhBMP-2
samples were purchased from MicroSolv (Eatontown, NJ). ProteinLoBind tubes were
purchased from Eppendorf (Hauppauge, NY). Agilent Zorbax 300-SB C3 column was
donated by Agilent technologies. Phosphate buffer saline was obtained from SigmaAldrich (St Louis, MO).

3.2.2 Equipment and Software
An Agilent 1260 Infinity HPLC was used for the method development and validation of
rhBMP-2. The equipment consisted of modules of a thermostat controlled autosampler
tray, a binary pump, and a photodiode array detector. Chemstation software (version:
C.01.07) was used for the instrument control and data processing. The pH of the buffers
and solution was measured using TruLab pH1310 (YSI, Inc., Yellowsprings, OH). The
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mass spectrometric detection/characterization of the peak-trapped samples before and
after forced degradation were performed on an AB Sciex 4000 Qtrap (Framingham, MA)
LC-MS/MS system. The software used for control and data acquisition was Analyst
software (1.5.2). For protein deconvolution algorithm, BioanalystTM (1.4) – Bayesian
protein reconstruct tool was used.

3.2.3 Preparation Of Mobile Phase, Stock Solutions,
Calibration Standards And Quality Controls
The aqueous mobile phase consisted of water with 0.1% TFA and the organic mobile
phase consisted of 90% acetonitrile with 0.1% TFA. Hanks Balanced Salts Solution
(HBSS) is a media, which has often been used in tissue culture and has comparable ion
concentration and osmolality to human plasma (Iyer et al., 2007c). Hence, it was
selected to simulate biorelevant release media conditions (Hanks, 1948; Iyer et al.,
2007c). As previously shown (Iyer et al., 2007c), Modified HBSS was prepared by
addition of 9.8 g of HBSS powder to 975 mL of water and 25 mL of 1M HEPES (Iyer et
al., 2007c). rhBMP-2 protein has been shown to be most stable at a pH of 4.5 (reduced
aggregation and denaturation (Luca et al., 2010)) and hence the pH was adjusted for
sample injection. After preparation, the solution was filtered through a 0.45 µm filter and
stored at 4°C. Stock solutions of 200 µg/mL, 100 µg /mL, and 10 µg /mL were prepared
in the biorelevant release media to cover the entire range of the calibration curve from
0.5 µg/mL -100 µg/mL. A series of calibration curves were prepared with ten calibration
levels equally distributed throughout the dynamic range: 0.5, 1.25, 1.5, 5, 10, 25, 50, 75,
and 100 µg/mL respectively. Quality control standard levels were selected bracketing
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the expected release range at 7.0, 20 and 45 µg/mL respectively and the LLOQ at 0.5
µg /mL. No sample preparation step was required. The release samples were thawed to
room temperature, vortexed for 1min, centrifuged on a tabletop centrifuge and aliquoted
into biocompatible inserts for injection.

3.2.4 Chromatographic Method Development Conditions
In silico characterization of rhBMP-2 was initiated using the sequence of the dimer for
human BMP-2 from UniProt to evaluate hydrophobicity (Consortium, 2014). ExPaSy
ProtParam by SwissProt was used as a software tool for a baseline theoretical
prediction of the physicochemical characteristics such as isoelectric point (pI) and
hydropathicity (Consortium, 2014; Walker, 2005). Chromatographic retention of a
protein can be significantly affected by its hydrophobic nature and dimension. A grand
average of hydropathicity (GRAVY) score of - 0.56 and pI of 8-9 was calculated by
ProtParam (Consortium, 2014). Hence taking into consideration the hydrophobicity of
the protein, the size of the dimer molecule, and pI of the protein, an HPLC column with
the following parameters: C3 column, 250 mm X 2.1 mm, 5 µm, 300 Å was selected
(Agilent Technologies, Santa Clara, CA).
Method development and optimization studies entailed sequentially evaluating the
process variables based on the peak area response, column efficiency, peak shape,
and robustness. Crucial optimization parameters that were assessed were: a) gradient
profile adjustment to reduce the retention time, b) combination of optimal velocity (i.e.,
flow rate) to minimize band broadening c) sample injection pH d) sample volume and e)
column temperature. Recombinant human BMP-2 has been found to be sensitive to pH
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changes. In the body, it is released at the site of fracture healing as a chemotactic and
osteoinductive agent in an acidic pH microenvironment (Hollinger and Wong, 1996;
Silver et al., 1988). An in-depth pH study relative to the physical stability and
conformation maintenance of rhBMP-2 in Luca et. al shows that the aggregation and
denaturation behavior of rhBMP-2 depends heavily on it’s media pH (Luca et al., 2010).
Therefore, pH studies with respect to response area and column efficiency were critical
for analysis reproducibility. Since pH 4.5 gave the best results, the response area and
column efficiencies at pH 2, 6 and 7 were normalized with respect to values at pH 4.5,
hence, pH 4.5 was selected as the control group. The column efficiencies in all cases
were > 2000 as required by USP guidelines (US Pharmacopeia, 2012). Results of pH
vs. normalized response area percentage and normalized column efficiency percentage
are shown in Figure 3-1. A one-way ANOVA with Dunnett’s multiple comparisons test
was used for the purposes of statistical comparisons at a significnce level of α = 0.05.
The ANOVA assumed normality and equality of variances due to limited standard
deviations of each data set. Diode array detection wavelength for rhBMP-2 was
selected by optimization of a combination of factors: a) wavelength (202nm-220nm), b)
bandwidth

(4nm-20nm)

and

c)

reference

wavelength

(280nm-360nm).

These

parameters were finalized based on a good signal to noise ratio, rhBMP-2 peak shape,
and optimized resolution between the drug product and major degradant peak during
forced degradation stability analysis. Recovery studies were also performed in water
and phosphate buffered saline (PBS) and compared to biorelevant media. Peak purity
analysis was performed using Chemstation software (Version: C.01.07) and the
threshold for passing peak purity was 990 out of 1000 for a pure peak.
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3.2.5 Method Validation
The method was validated according to the FDA Bioanalytical Guidelines (FDA, 2001;
Geenen et al., 2011) since Hanks’ balanced salts solution was a cell culture medium
[10]. Validation experiments consisted of selectivity, linearity, precision and accuracy,
recovery, and limit of quantification. Six calibration curves were prepared and evaluated
for linearity. A polynomial regression model (R2> 0.99) with least squares regression
was used for the calibration curve based on chromatographic peak area vs.
concentrations of the drug substance. The limit of detection was calculated using three
times the signal to noise. Furthermore, the limit of quantification was evaluated as ten
times the signal to noise; however, a higher experimental value, which could be reliably
and repeatedly quantified with an accuracy of 80-120% and a relative standard
deviation (RSD) of < ± 15% was selected (0.5 µg /mL). Intra-day and inter-day precision
and accuracy were calculated for three batches (n=9). System suitability (SST) was
evaluated using (n=6) replicate injections of rhBMP-2 at a concentration of 20 µg/mL.
Criteria for passing SST was ± 2% relative standard deviation percentage for precision,
column efficiency (> 2000), and a tailing factor <2, according to USP guidelines for
method validation of chromatographic methods (US Pharmacopeia, 2012).
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Figure 3-1. Sample injection pH vs. Normalized response area/column efficiencies
A one-way ANOVA with Dunnett’s multiple comparisons test was used for the purposes
of statistical comparisons.

50

Recovery studies were performed in water and PBS and also in modified HBSS by
spiking pre-analyzed QC samples with known concentrations of the drug substance.

3.2.6 Stability Of rhBMP-2
Proteins tend to aggregate at low concentrations and are highly labile to minor
fluctuations in temperature; therefore, evaluating the stability of rhBMP-2 was critical for
the in vitro release experiments. Stability studies were carried out at two different
concentrations (2 µg/mL and 15 µg/mL, respectively), three different temperatures (i.e.,
4°C-autosampler temperature, 22°C-room temperature, and 37°C-physiological body
temperature). Incubation was performed at two-time points: 12hr and 24hr, respectively.
Storage stability and freeze-thaw cycle stability studies (1 and 2 cycles) were also
carried out at -20°C and -70°C, respectively.

3.2.7 Stability Indicating Method Conditions
Stability studies are a crucial part of method validation studies to determine the
presence of interfering degradant products, which might appear in the formulation
during bioprocessing, storage, handling, and/or transportation. They also shed light on
the degradant detection and resolution ability of the optimized method. Therefore, it is
necessary to investigate the stability of rhBMP-2 in the biorelevant media during the in
vitro release testing process. The conformation and stability of a protein are a measure
of its therapeutic value (Hermeling et al., 2004). Stress testing for the drug substance
was performed using acidic (0.1M HCl), basic (0.1M NaOH), oxidative (i.e., peroxide-
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30%) and temperature (70°C) at 24hr, 48hr, and 72hr stress conditions, respectively at
a concentration of 45 µg /mL. Since no degradation products were observed initially with
the method’s 9min run time, the run time was increased to 20min to help in the
detection of possible late eluting degradation products (US Pharmacopeia, 2012) .

3.2.8 Differential Isoforms of recombinant human Bone
Morphogenetic Protein -2
rhBMP-2

is

a

chemo-attractant

molecule

that

is

both

osteoinductive

and

osteoconductive (Li and Wozney, 2001). Endogenously, it attracts the mesenchymal
stem cells to the site of trauma and injury to facilitate the process of bone regeneration.
rhBMP-2 is most commonly cloned in Chinese Hamster Ovary(CHO) cell lines. Since
the folding and conformation of a protein is central to it being therapeutically bioactive,
CHO cells are adept at post- translationally processing the BMP-2 homodimer (Kim et
al., 2012). This results in six distinct isoforms of BMP-2 each of which can have varying
combinations of 5-9 mannose units per monomer attached to its N-linked glycosylation
site (Israel et al., 1992). Each monomer of rhBMP-2, depending upon its posttranslational processing, could either begin with a glutamine at position 283 (Q283) or
with an additional 17 amino acids with a threonine at position 266 (T266). Glutamine
conversion to pyroglutamate at physiological pH and in solution at the N-terminal end is
often observed in proteins and hence also in rhBMP-2. The glutamine undergoes cyclic
conversion to pyroglutamate (Q’283) leading to a loss of -17.03Da (Reimer et al., 2011).
However, since the rhBMP-2 is a dimeric molecule, about 6 different isoforms are
possible. Each of these isoforms can, in turn, contain a combination of 5-9 mannose
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residues on each of the monomer, giving rise to heterogeneity and complexity in the
protein. All the post-translationally modified isoforms of rhBMP-2 are found in the drug
formulation and have comparable bioactivity and bone induction ability as evaluated in
Porter et. al. (Porter et al., 2004).

3.2.9 Qualitative characterization of rhBMP-2 glycoforms
and forced degradation products using mass
spectrometry
An exploratory mass spectrometry survey was carried out on the peak-trapped samples
from the HPLC, for qualitative characterization of the changes affecting the rhBMP-2
molecule. The rhBMP-2 drug product (both non-stress treated and stress treated - as
mentioned in section 3.2.7) samples were injected into the Agilent 1260 Infinity HPLC at
a concentration of 45 µg/mL. The rhBMP-2 peak, degraded peak 1(DP1) and degraded
peak 2(DP2) (as shown in Figure 3-4A and B in results section) were peak trapped and
collected in low protein bind eppendorf tubes. These were injected by direct infusion at
15 µL/min into AB Sciex 4000 Qtrap mass spectrometer. The difference in molecular
weights (based on m/z) between the control samples (samples which had not been
subjected to stress/forced degradation) and peaks trapped from acid, base, peroxide
and temperature subjected stressed samples were investigated. An Enhanced MultiCharge (EMC) scan mode was selected over a Q1 MS mode during mass spectral
characterization since rhBMP-2 drug product is a relatively large protein molecule
(29kDa-32kDa) which acquires multiple charges during the ionization mode and has
multiple isoforms. The EMC scan mode in 4000 Qtrap facilitates the transfer of multi53

charged ions only and the low charged ions escape out of the linear ion trap (LIT) during
the set delay time. Although there is some loss of multiply charged ions during this
delay time; the loss of singly charged ions are much more in relative comparison. A
scan range of 1200-2800 m/z was selected. Q0 trapping was switched on and LIT fill
time of 10ms was applied as well as a Q3 empty time of 30ms. The MCS barrier was
set at 3V; declustering potential at 57V and collision energy at 55V. Infusion rate was
set at 15 µL/min. Since the formulation is a complex mixture of isoforms of the protein,
initial tuning of the method was focused on acquiring a maximum of signal/noise ratio
and reproducibility for the dominant ions. The mass spectra were deconvoluted using
Bioanalyst software and the Bayesian protein reconstruct algorithm. The deconvolution
results were then interpreted using the GlycoMod tool of ExPASy (SIB Bioinformatics
Resource Portal) to calculate the number of mannose units present on the intact protein
(Cooper et al., 2003).

3.3 RESULTS AND DISCUSSION
3.3.1 Method Development
A stepwise gradient profile was used with the following conditions: initially at 70%- 0.1%
TFA (Mobile Phase A) and 30%- 90% acetonitrile with 0.1% TFA (Mobile Phase B;
followed by 0.2-1.7 min. increased to 85% Mobile phase B; 3.5 – 5 min. at 95% (Mobile
phase B); and finally 7-9 min. re-equilibration at initial conditions (70% Mobile Phase A).
The gradient was run in a combination with velocity between 0.4mL/min to 0.5mL/min
with a total run time of 9min and an rhBMP-2 peak retention time of 3.44min. The pH of
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the media is crucial to the stability of rhBMP-2, chromatographic studies were
conducted for improvement of peak shape, peak area response and column efficiency
with injection sample pH at 2 (pH matching with mobile phase pH 2), 4.5, 6 and 7.4.
Figure 3-1 in the methods section of this chapter shows the normalized response area
and column efficiency vs. sample injection pH. It was observed that the optimal peak
shape, area response and column efficiency during the optimization studies were at pH
of 4.5. A one-way ANOVA was performed with Dunnett’s multiple comparisons test.
Since pH 4.5 showed the best response area and column efficiency mean values, it was
used as the control column for multiple comparisons in the Dunnett’s test. The results
were reported as normalized percentage for both peak area response and column
efficiency.

The normalized mean peak response area for n=6 samples at pH 2.0 was 76.80 ± 1.83
%, at pH 4.5-recorded mean was 100.00 ±3.25 %, at pH 6 the response area showed a
considerable decrease to 69.04 ± 1.39, and with a further reduction at pH 7.4 to 60.04 ±
2.22. Results of the ANOVA multiple comparison Dunnett’s test showed that response
area at pH 4.5 was significantly different from each pH at 2, 6 and 7.4 at a significance
level of α=0.01 with (p< .0001). The normalized percent average column efficiency
calculated for n=6 samples were 97.96 ± .70 for pH 2; 100 ± .93 for pH 4.5; 95.58 ± 1.07
for pH 6 and 92.51 ± 3.12 for pH 7.4. A one-way ANOVA was used with a multiple
comparisons Dunnett’s test to evaluate if the mean column efficiencies were
significantly different from pH 4.5. It was found that the mean of pH 4.5 was significantly
different from pH 7 at a significance level α=0.01(p< .01).
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Peak shape, response and column efficiency with respect to column temperature was
evaluated at 25°C, 37°C, 40°C and 50°C. Optimal peak shape and response area was
observed at 40°C. Sample injection volume studies were also conducted with injection
volumes of 15, 20, 25, 35, 45, 55 and 60µL in a 120 µL sample loop. Ultimately, a 60µL
injection, with minimal carryover at the higher limit of quantification, was used to obtain
a linear dynamic range (0.50 to 100 µg/mL). For the DAD a wavelength of 217nm, a
bandwidth of 14nm and a reference wavelength of 280nm was selected to get a robust
peak shape and sufficient resolution between the rhBMP-2 peak and degradant product
1(dp1).

3.3.2 Method Validation
3.3.2.1 Selectivity, Linearity, Limits of Detection (LOD) and Limits of
Quantification
Selectivity for the assay was determined by testing if the formulation excipients
interfered or had a similar retention time as the rhBMP-2 on the HPLC system. Each
1ml of INFUSE® Bone Graft formulation consists of 1.5mg of rhBMP-2 protein; 0.1mg
sodium chloride; 5.0 mg sucrose; 25mg glycine; 3.7 mg L-glutamic acid and 0.1mg
polysorbate 80 (FDA Rockville, 2007b). Individual solutions of the excipients were
prepared at the concentration that they are present in the original formulation as well as
a mixture of all the excipients but without rhBMP-2 and injected into the column to
observe the presence of interfering excipient peaks in the HPLC method. No interfering
peaks were observed from any of the excipients. Peak purity evaluations with a cut off
at 990 out of 1000 resulted in a peak purity similarity factor of 997 out of 1000;
56

therefore, the peak was pure as by spectral comparison. Figure 3-2 is a representative
chromatogram of a blank sample (A), LLOQ (B), and 20µg/mL concentration sample
(C). A polynomial regression model was used for three runs (n=6), R2 > 0.99. The
reverse predicted residuals from the calibration curve have been provided in Table 3-1.
The concentration of the reverse predicted residuals have been reported as percent
difference from nominal (%DFN) and ranged from 9.67% at the LLOQ of 0.5 µg/mL to –
6.27%. The LOD was calculated as three times the signal to noise and was found to be
0.10 µg/mL.

57

Figure 3-2. Representative chromatograms of rhBMP-2
(a) blank medium, (b) 0.5 µg/mL (LLOQ), (c) 20 µg/mL.
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3.3.2.2 Intra-day and Inter-Day Precision and Accuracy
Precision and accuracy of the method are reported in Table 3-2 as %RSD and %DFN
respectively. Inter-day and intra-day precision for the QC’s were carried out at three
different levels (7 µg/mL; 20 µg/mL and 45 µg/mL) for release concentrations which
were pertinent to release from the biorelevant model. A global calculation for the three
different QC levels, for three runs (n=9), was estimated. %RSD was found to be from
0.64% to 1.90%. %DFN was observed to be between -3.70% to 0.14%. Precision and
accuracy of quantitation of the rhBMP-2 protein was also evaluated for the LLOQ at 0.5
µg/mL. Estimation of global calculation for the LLOQ (0.5 µg/mL) for all the three runs
showed a %RSD of 3.49% and %DFN of 6.67%, respectively. Precision and accuracy
for the individual inter-day runs have also been presented in Table 3-2.
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Table 3-1. Reverse predicted concentration residuals of rhBMP-2
Run
number

R2

Nominal Concentration (µg/ml)
0.500

1.25

1.50

5.00

10.00

25.00

50.00

75.00

100.00

1

0.532

1.32

1.58

4.69

10.09

24.82

50.23

75.02

100.03

0.999

2

0.544

1.38

1.54

4.74

10.19

24.64

50.67

74.83

99.96

0.996

3
Mean

0.569
0.548

1.19
1.30

1.62
1.58

4.63
4.69

10.25
10.18

24.50
24.65

50.02
50.31

74.86 99.64
74.84
99.88

0.998

S.D.
%RSD
%DFN

0.02
3.44
9.67

0.09
7.49
3.73

0.04
2.53
5.33

0.06
1.18
-6.27

0.08
0.79
1.77

0.16
0.65
-1.39

0.33
0.66
0.61

0.18
0.25
-0.22
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0.21
0.21
0.12

Table 3-2. Precision and accuracy data for rhBMP-2 QC’s
Run Number
1

Nominal Concentration (µg/ml)
0.50
7.00
20.00
0.56
6.82
20.37
0.54
6.71
20.05
0.55
6.78
20.26

45.00
45.29
44.29
45.21

Mean
S.D.
%R.S.D.
%DFN
2

0.55
0.01
1.82
10.00
0.53
0.57
0.51

6.77
0.06
0.82
-3.29
6.65
6.68
6.47

20.23
0.16
0.80
1.13
19.60
19.63
20.68

44.93
0.56
1.24
-0.16
45.08
44.93
44.86

Mean
S.D.
%R.S.D.
%DFN
3

0.53
0.03
5.36
7.60
0.55
0.52
0.47

6.56
0.12
1.77
-5.73
6.83
6.99
6.74

19.97
0.62
3.08
-0.16
19.65
19.98
20.04

19.89
0.11
0.25
-0.10
45.67
45.10
45.01

Mean
S.D.
%R.S.D.
%DFN
Global Calculation
Mean
S.D.
%R.S.D.
%DFN

0.51
0.04
7.87
2.67

6.85
0.13
1.85
-2.10

19.89
0.21
1.06
-0.55

45.26
0.36
0.79
0.58

0.53
0.02
3.49
6.67

6.74
0.13
1.90
-3.70

20.03
0.18
0.88
0.14

45.05
0.28
0.64
0.11
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3.3.2.3 System Suitability and Recovery
System suitability helps to establish the appropriateness of the developed analytical
method with respect to the chromatographic modules used on a routine basis. For the
developed rhBMP-2 method, system suitability was evaluated at a concentration of 20
µg/mL with 6 replicate injections (n=6). Results of system suitability have been shown in
Table 3-3. A global calculation was performed for all the injections and was reported in
terms of mean and %RSD for all the parameters such as precision, retention time,
efficiency and tailing factor. The %RSD on precision was found to be 1.45%; retention
time 0.02%; column efficiency 0.23% and tailing factor 1.75%. The validated analytical
method developed for rhBMP-2 in biorelevant media was also tested for recovery of
rhBMP-2 drug in water: ACN (70:30) and Phosphate Buffered Saline (PBS). Known
concentration samples (20 µg/mL) were spiked with 3 µg/mL of rhBMP-2 protein (n=3
replicates). a) Water: ACN (70:30) showed a recovery% of 87.14 ± 0.23 b) PBS showed
a recovery % of 100.06 ± 6.92 and c) in modified HBSS a recovery % of 102.07 ± 4.11
were observed.
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Table 3-3. System suitability of 20µg/mL rhBMP-2 injection
Injection No.
1
2
3
4
5
6
Global Calculations
Mean
% RSD

Precision
(20µg/mL)
20.05
20.26
19.60
19.63
20.04
20.25

Retention time
(min)
3.44
3.44
3.44
3.44
3.44
3.44

Efficiency
5309.69
5345.77
5323.68
5329.38
5333.79
5323.90

Tailing
factor
1.80
1.72
1.75
1.75
1.72
1.77

19.97
1.45

3.44
0.02

5327.30
0.23

1.75
1.75
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3.3.2.4 Stability of Drug Substance
Stability was evaluated at low and medium concentration levels (i.e., 2 µg/mL and 15
µg/mL) and the data are shown in Table 3-4. Samples were stable when kept at 4°C
(autosampler temperature), 22°C (room temperature) and 37°C (physiological body
temperature). The recovery % of the samples was within the acceptable range of 90110% for a period of 24hrs. Protein conformation (secondary and tertiary folding)
stability has been known to be effected by freeze-thaw cycles, thereby leading to protein
denaturation and aggregation (Bhatnagar et al., 2007; Pikal-Cleland et al., 2000).
Hence, freeze-thaw stability of the samples was evaluated at the primary storage
temperatures for the samples (-20°C and -80°C). The results for n=3 replicate samples
are shown in Table 3-5. Although the recovery after one freeze-thaw cycle was within
90-110%, recovery after two freeze thaw cycles in both -20°C and -80°C indicated a
reduction by 14.79% and 17.13%, respectively. To reduce the need for more than one
freeze-thaw cycle for future use, the stock samples when required to be stored in
solution form, were aliquoted into separate protein loBind tubes at low volumes for
storage (0.100ml).

3.3.2.5 Stability Indicating Studies- Forced Degradation Analysis
Forced degradation studies in the biorelevant release media helped in the
characterization of rhBMP-2 drug remaining after 24hr, 48hr and 72hr under stress
testing conditions. Results of the forced degradation studies have been represented in
the bar graph in Figure 3-3. Acid forced degradation showed a recovery percentage of
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Table 3-4: Stability of rhBMP-2 in modified HBSS media (n=3 experiments)
Nominal
Concentra
tion
(µg/ml)
2 µg/ml
Mean
SD
15 µg/ml
Mean
SD

Autosampler temperature
Stability (4°C)
(Recovery%)

Room temperature
Stability (22°C)
(Recovery%)

Physiological temperature
Stability (37°C)
(Recovery%)

12hr

24hr

12hr

24hr

12hr

24hr

93.71
8.65

98.43
5.40

91.06
5.56

90.12
5.17

91.00
3.36

92.51
4.50

99.97
3.80

99.96
2.56

100.24
2.71

99.13
1.11

102.32
2.66

95.82
5.94

Table 3-5: Freeze-thaw stability of rhBMP-2 at different temperatures (n=3
experiments)
Temperature conditions

-20°C
-70°C

No. of freeze thaw cycles
(Recovery% ± SD)
1 freeze thaw cycle
2 freeze thaw cycle
100 ± 5.56
85.21 ± 4.79
105.36 ± 2.87
82.87 ± 6.94
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Figure 3-3. rhBMP-2 recovery % in stressed samples for acid, base, peroxide and
temperature stress testing for 24hr, 48hr and 72hr time points.
All statistical comparisons between samples been made with the control at 4°C at their
respective time points. p<.001(**); p<.0001(***); p<.00001(****).
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94.53 ± 2.85 %, 78.27 ± 0.85 % and 62.93 ± 2.99 % after 24hr, 48hr, and 72 hr,
respectively. Degradation studies in base showed a recovery percentage of 90.40 ±
8.66 %, 76.37 ± 4.19 % and 71.66 ± 2.69 % respectively. Oxidative forced degradation
yielded a recovery % of 95.77 ± 1.22 %, 84.66 ± 5.72% and 73.42 ± 1.41 %
respectively. Temperature based forced degradation at 70°C showed a much lower
level of recovery of rhBMP-2 protein. The recovery percentage of rhBMP-2 at 24hr, 48hr
and 72hr were 76.47 ± 1.14%, 63.74 ± 1.42% and 37.62 ± 6.63% respectively. A oneway ANOVA with Dunnett’s multiple comparisons test was performed at a significance
level α=0.01. The specific time points (24hr, 48hr, and 72hr) for each of the
corresponding stress treated samples were compared with their control at 4°C at the
same time point to observe if the means were significantly different. For the 24hr time
point, the acid (p=0.1866), base (p= 0.0266) and the peroxide (p= 0.3163) were not
significantly different from the control at 4°C but the recovery percentage of rhBMP-2 for
temperature was significantly less (p ≤0.0001) than the control. A one-way ANOVA with
Dunnett’s multiple-comparisons test at a significance level α=0.01 for 48hr however,
showed a greater difference in means when compared to the 48hr control at 4°C. At the
48hr time point all the means were significantly different and decreased relative to the
control: acid (p=0.0002); base (p≤ 0.0001); peroxide (p=. 0035) and temperature (p≤
0.0001). Similarly, for the 72hr time point, the data showed a further decrease in means
as compared to the control sample at 4°C for 72hr. All the stress-tested samples had
significantly different and lower means: acid (p ≤0.0001); base (p ≤0.0001); peroxide (p
≤0.0001) and temperature (p ≤0.0001). Temperature based stress testing also revealed
the presence of three resolved degradation products (DP), which have been labeled as
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DP1 (retention time= 1.8min, observed only in the 72hr stress tested sample at 70°C),
DP2 (retention time= 3.8min) and DP3 (retention time= 5.1min). The representative
chromatograms for the stress-tested samples have been shown in Figure 3-4A and B.

3.3.3 Qualitative mass spectral characterization of
glycoforms of BMP-2 and changes observed in
stressed samples during forced degradation
rhBMP-2 is expressed in Chinese Hamster Ovary (CHO) cell lines as a precursor
propeptide. During post-translational processing, heterogeneity in the sequence of
amino acids at its N-terminal end leads to a total of six different types of isoforms.
Therefore, the rhBMP-2 formulation consists of three distinct N-terminal isoforms:
a) Q283/Q283 in which both monomers are processed at the glutamine 283 sites
b) Q283/T266 one monomer processed at the glutamine site and one monomer
processed at the threonine site and c) T266/T266 both monomers processed at
threonine site (Israel et al., 1992). It has also been detected that the glutamine at the Nterminal end converts into pyroglutamate (Q’) in solution form in vitro and in vivo and
this leads to a loss of -17.03Da (Reimer et al., 2011). The glutamate to pyroglutamate
conversion results in three additional isoforms: d) Q’283/Q’283 in which both glutamines
are converted into pyroglutamate e) Q283/Q’283 in which one glutamine is converted
into pyroglutamate f) Q’283/T266 with one pyroglutamate and one threonine (Porter et
al., 2004). Individually the above isoforms also give rise to a diverse range of
glycoforms depending upon the number of mannose residues (generally 5-9), attached
to the N-linked glycosylation site. Table 3-6 is a list of some of the glycoforms with their
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predicted and experimental molecular weights as observed in the rhBMP-2 non-stress
treated control samples.

The effects of stress conditions on rhBMP-2 were explored with peak-trapped samples
from an Agilent 1260 HPLC that were subsequently injected onto the LC-MS by direct
infusion (at 15µL/min) into an AB Sciex 4000 Q trap. After deconvolution, a distribution
is obtained covering a range of glycoforms from 29kDa- 32kDa. The deconvoluted mass
reconstruction of the spectrum has been shown in Figure 3-5. The temperature based
stress treated sample showed the major decrease in response area in chromatograms,
presence of degradation peaks (DP) and also changes in the mass spectra.
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Figure 3-4A. Representative chromatograms for rhBMP-2 stress studies (a) Acid (b)
Base
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Figure 3-4B. Representative chromatograms for rhBMP-2 stress studies (c) Peroxide
(d) Temperature.
Degradant Peaks: DP1, DP2 and DP3 were observed only in temperature stress treated
samples.
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The major degradation pathways for a protein are deamidation, oxidation, hydrolysis
and reduction (Patel et al.). These reactions frequently cause chemical conversions and
degradation in the protein molecule. The chemical changes lead towards inability in
maintaining the essential secondary and tertiary conformation of the protein structure.
Distortion in folded structure of the protein molecule eventually results in fragmentation,
aggregation, and precipitation of the biotherapeutic protein (Bhatnagar et al., 2007;
Patel et al.). An in-depth survey and comparison of the deconvoluted mass spectra for
the control and forced degraded samples revealed the most frequent and repetitive
shifts in molecular weight was of +13Da; +16Da; +64Da. The predicted structural
changes associated with these observed molecular shifts were as follows: deamidation
of asparagine: deamidation of Asp leads to a gain of 0.982 Da due to the conversion of
a –NH2 group to an –OH group (Yang and Zubarev, 2010).
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Figure 3-5. Deconvoluted masses of rhBMP-2 peak trapped sample at 3.44 min.
Three distinct distributions for the glycoforms a) Q283/Q283, b)Q283/T266, and c)
T266/T266 were observed because of 5-9 mannose residues per monomer.
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Table 3-6. rhBMP-2 glycoform mass assignment
Type of
differential
Isoform

No. of
Mannose
residues

Predicted mass
of glycoform
(Avg. mass)

Experimental mass
of glycoform
(Avg. mass)

Δm%

Q’283/Q’283
Q’283/Q283
Q283/Q283
Q’283/Q’283
Q’283/Q283

(Mannose)13
(Mannose)13
(Mannose)13
(Mannose)18
(Mannose)18

27945.433
27929.433
27913.434
28692.147
28676.148

27945.161
27928.131
27913.603
28692.602
28675.572

-0.0009
-0.0046
-0.0006
0.0016
-0.0020

Q283/T266
Q283/T266
Q283/T266
Q283/T266
Q283/T266
Q’283/T266
Q’283/T266
Q283/T266

(Mannose)5
(Mannose)10
(Mannose)12
(Mannose)12
(Mannose)15
(Mannose)15
(Mannose)5
(Mannose)5

28696.591
29523.302
29831.588
29847.587
30286.016
30268.986
28631.562
28615.563

28695.078
29524.047
29831.852
29847.536
30288.610
30271.580
28634.977
28617.947

-0.0053
0.0025
0.0009
-0.0002
0.0086
0.0086
0.0112
0.0083

T266/T266
T266/T266
T266/T266
T266/T266

(Mannose)8
(Mannose)9
(Mannose)12
(Mannose)18

31117.258
31247.402
31701.830
32690.683

31116.446
31251.383
31700.302
32693.065

-0.0026
0.0127
-0.0048
0.0073

Table 3-7. Mass shift in temperature stress treated samples of rhBMP-2
Predicted Degradation
Reaction

Type of
Glycoform

1. Cyclization of Glu
2. Deamidation of Asp
3. Deamidation of Asp
4. Oxidation of Met/Trp
5. Oxdation of Met/Trp

Q283/T266
Q283/T266
Q283/T266
Q283/T266
Q’283/Q’283

Non-stress
treated
Mass
30205.988
30905.729
29847.587
28891.850
28595.002
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Stress
treated
mass
30188.592
30919.477
29860.222
28908.286
28659.512

Expected
Δm
(Da)
- 17.030
+12.766
+12.766
+16.000
+64.000

Observed
Δm
(Da)
- 17.396
+12.360
+12.635
+16.440
+64.500

rhBMP-2 has 14 asparagine (Asp) residues in its sequence. Asp residues guarded by
neighboring hydrophobic and branched chain amino acids exhibit lower rates of
deamidation as compared to Asp residues with neutral, polar and hydrophilic amino
acids such as glycine and serine (Tyler-Cross and Schirch, 1991). On comparison of the
stressed samples to the non-stressed samples, the most frequent observation was a
gain of +13 to +14Da. It was observed that the Q283/T266 glycoform with 10 and 15
mannose residues showed an increase in molecular weight of +12.36Da (from 30905.73
to 30919.48Da) and +12.64Da (from 29847.59 to 29860.22 Da), respectively. Therefore,
this deamidation of 13 asparagine residues in rhBMP-2 is most likely due to the high
stress temperature of 70°C for 3 days. Similar observations have also been reported in
Porter et. al (Porter et al., 2004) when the protein was subjected to temperature stress
at 37°C for 7 days. Further analysis by high resolution/accurate mass MS and NMR will
be required to confirm the exact structural changes in the glycoforms for all the stresstreated samples.

Oxidative degradation: Another frequent pathway for degradation of proteins is by
oxidative degradation. The amino acids, which are most susceptible to oxidation, are
methionine, cysteine, tryptophan and tyrosine (Li et al., 1995). Oxidation generally
entails the gain of oxygen and hence, increases in the molecular weight by +16Da;
+32Da and +64Da depending upon the number of amino acid residues oxidized.
rhBMP-2 dimer shows the presence of 2 tryptophan and two methionine residues on
each monomer (hence a total of 4 tryptophan and 4 methionine on each dimer) (Ji et al.,
2009). An analysis of the molecular weights of the different glycoforms predominantly
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revealed shifts in molecular weights of +16 or +64 Da (that can be attributed to primarily
methionine or tryptophan oxidation) (Patel et al.). Predicted oxidative molecular weight
increase was mostly observed in Q283/T266 samples an increase in molecular weight
of +16.44Da for a Mannose 7 glycoform (from 28891.850Da to 28908.286Da) and a
Q’283/Q’283 glycoform of +64.50Da (from 28585.002 to 28659.512Da). The various
mass shifts have been listed in Table 3-7. The qualitative characterization information
generated from these stress studies will help in future in-depth structural conformation
studies using high-resolution MS and NMR.

3.3.4 Bioanalytical method application to samples of
‘biorelevant’ in vitro release study
The developed method was used to quantify release samples from a novel biorelevant
model. Initial stability degradation studies addressed in section 3.2.4. and Table 3-4
reveals the stability of the formulation at 37°C in the biorelevant release media. The
release was measured in modified Hanks Balanced Salts solution at a pH of 4.5 ± 0.1
and a pH 7.2 ± 0.1 at temperature conditions of 37°C. Approximately 400 samples have
been analyzed using the above-validated method; Figure 3-6 is a real-time in vitro
release study sample from the biorelevant in vitro model. Chromatographic interference
from degradation products has not been observed in the samples thereby indicating the
robustness of the method.
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Figure 3-6. Chromatogram of 24hr. release sample from real time in-vitro study.

77

3.4 CONCLUSION
An HPLC stability indicating method was developed and validated for the first time for
quantification of rhBMP-2 protein formulation in a biorelevant release media. The
method will help facilitate analysis and quantification of rhBMP-2 protein released from
a collagen scaffold based implant (INFUSE® Bone Graft) in a novel biorelevant in vitro
model for release testing of implants. All six isoforms of rhBMP-2 and some specific
glycoforms of each isoform were also detected in the release media using a triple
quad/linear ion trap MS. Stressed forced degraded samples revealed shifts in molecular
weights of the various glycoforms when compared to non-stress treated rhBMP-2.
Future work will include use of tools such as high resolution/accurate mass (HR/AM)
MS and NMR for extensive detection and characterization of specific structural and
conformation changes that stress induces in the rhBMP-2 glycoprotein. This will be a
step towards bridging the gap in higher order structural characterization changes
induced by stress in complex biotherapeutic protein formulations and biologics.
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CHAPTER 4

4

A Novel Biorelevant In Vitro Drug Release Model to
Characterize Release of Recombinant Human Bone
Morphogenetic Protein-2 from an Absorbable Collagen
Sponge Scaffold

4.1 INTRODUCTION
4.1.1 Biorelevant In Vitro Release Testing
In vitro dissolution and release testing have been used as crucial tools for establishing
bioequivalence between dosage forms and for biowaivers in immediate release solid
oral dosage forms (Yu et al., 2002). Extended controlled release non-oral dosage forms
also called as ‘special/complex’ dosage forms, such as carrier based protein implants,
drug-eluting stents, liposomes, nano-particles are often positioned in unique
physiological environment. Their primary functionality is to release the drug substance
over an extended period of time in controlled and requisite quantities to meet the
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targeted therapeutic range. After implantation drug biodistribution for ‘complex’ dosage
forms occurs in surrounding tissues and compartments that are often difficult to access.
This makes the sampling of the drug in all the tissue samples challenging. As a result
exploration of the release mechanism and pharmacokinetic profile of the drug is
considerably difficult in comparison to immediate release dosage forms such as tablets
and suspensions. In such cases an in vitro release test can be of additional value in
studying the release of the drug substance from the carrier scaffolds such as collagen,
PLGA and liposomes. A dissolution or release test study design should ideally be a
representative and surrogate test for in vivo release. It should be easy to perform;
reproducible and robust yet circumvent the simulation of major physiological factors that
might affect the dosage forms performance in vivo. Such dissolution or release tests
can be said to be clinically biorelevant and can act as quality control tests. They can
help in predicting batch-to-batch variability and minor formulation changes between
batches during the manufacturing process.

Standard USP apparatuses that have been established and work well for immediate
release dosage forms such as tablets and suspensions are often not relevant to
controlled release parenterals. They fail to capture critical clinically biorelevant in vivo
parameters such as low fluid volume surrounding the dosage form, vascularity and flow
directionality, complications during the sampling procedure (e.g physical separation of
the dosage form such as carrier hydroxyapatite particles, liposomes and nanoparticles
from the release media). Amongst the USP apparatuses, USP-IV is the preferred
apparatus in literature for release testing of complex release parenterals (Cardot and
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Tomic, 2015; Sievens-Figueroa et al., 2012; Thomas, 2016). Various modifications have
been applied in the past to standard USP-IV flow through cell for the release testing of
microspheres, liposomes and drug eluting stents e.g dialysis adapter settings, design of
vessel simulating flow through cell (Bhardwaj and Burgess, 2010; Seidlitz et al., 2011a;
Zolnik et al., 2005). These adaptations have generally been made to facilitate ease of
sampling and achieve representative cumulative release profiles. In many investigations
such as Seidlitz and co-workers, 2011, the adaptations to the USP-IV were designed to
better simulate physiological microenvironment and in vivo parameters that might affect
drug release and biodistribution into complex tissue compartments (Seidlitz et al.,
2011a).

The primary objective of this research was to develop a biorelevant release study
design for a novel dosage implant INFUSE® Bone Graft (a collagen carrier based
biodegradable scaffold with a protein rhBMP-2 as the drug substance). The first step
was exploring conventionally available dissolution/release testing methods for implants
such as ‘sample and separate’ and ‘USP-IV flow through cell’. Due to high variability in
results and incomparable release profiles obtained from sample and separate and USPIV, our next step was to design and develop a novel biorelevant in vitro model for
release testing of the implant graft. The model was designed to simulate a) low fluid
volumes with b) membrane separated multi compartments of 3-8mL and c) flow
directionality requisite for drug release in implants. It was primarily intended to facilitate
the testing of carrier-based scaffolds (such as collagen and hydroxyapatite) in which the
filler carrier material of the implant might occupy the central compartment mostly or
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completely. It was also designed to simulate perfusion of the extended controlled
release implants by parallel low flow rates. Lastly, it also simulated in its design if
required physical separation of the dosage form from the media such as for
release/dissolution testing of microspheres and liposomes. The model was expected to
provide an evaluative in vitro relationship (IVR) between formulations of rhBMP-2 (the
drug substance of the selected implant). The novel in house developed model was then
evaluated by testing if it is discriminatory between two different formulations of rhBMP-2
using similarity (f2) and difference (f1) factors.

4.2 MATERIALS AND METHODS
4.2.1 Materials
INFUSE® Bone graft was generously donated by Medtronic (Minneapolis, Minnesota,
USA). Osteograf/N-300 was purchased from Dentsply Sirona (Philadelphia, PA, USA).
Modified Hanks Balanced Salts Solution (HBSS-without phenol red and sodium
bicarbonate) and 4-(2-hydroxy ethyl) piperazine-1-ethanesulfonic acid (HEPES buffer,
1 mM) were purchased from Sigma-Aldrich (St. Louis, MO, USA). HPLC grade water
was purchased from Fisher Scientific (Waltham, MA, USA). HPLC grade acetonitrile
was purchased from VWR (Radnor, PA, USA) and trifluoro acetic acid was purchased
from EMD Millipore (Billerica, MA, USA). Sample materials for creating the body of the
model such as polycarbonate, polytetrafluoro ethylene (PTFE), teflon and poly ether
ether ketone (PEEK) were provided by in-house engineer Mike Grieve at Virginia
Commonwealth University, Richmond, VA, USA. The material for the construction of the
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body of the model (polycarbonate) was obtained from Piedmont Plastics (Richmond,
VA, USA). Three-way flow valves and polypropylene tubing connectors were purchased
from Spectrum Laboratories (Rancho Dominguez, CA, USA). Protein low binding
membrane materials: regenerated cellulose (47mm diameter; 0.45 µm pore size), poly
tetra fluoro ethylene (47mm diameter; 0.45 µm pore size), polycarbonate (47mm
diameter; 0.45 µm pore size), cellulose acetate (47mm diameter; 0.45 µm pore size)
and poly ether sulfone (PES) (47mm diameter; 0.80 µm pore size) were obtained from
GE Life Sciences (Pittsburgh, PA, USA). Protein low bind silicon pump tubings
(Masterflex, platinized and formulation grade) were purchased from VWR (Radnor, PA,
USA). Low flow peristaltic pumps (0.03 to 8.2 mL/min.) were purchased from VWR
(Radnor, PA). Polysorbate 80 was purchased from Sigma-Aldrich (St. Louis, MO, USA).

4.2.2 Description of the dosage forms tested
INFUSE® Bone graft:
INFUSE® Bone graft is a biodegradable locally acting implant that helps in
osteoinduction and bone regeneration (FDA Rockville, 2007a; Urist, 1965). The dosage
form has been used for oral maxillofacial surgery, healing of tibial shaft fractures and
spinal fusion surgeries (McKay et al., 2007). It consists of two main components a
collagen based scaffold for release over an extended period of time and bone
morphogenetic protein-2 (BMP-2), the protein that helps in bone regeneration and
healing (Carragee et al., 2011). BMP-2 is found endogenously in the body and is
predominant during embryonic stages of growth and differentiation in humans
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(Carragee et al., 2011). It is a cytokine belonging to the Transforming Growth Factor-β
family and due to its high rate of systemic clearance has a short residence time (FDA
Rockville, 2007a; Urist, 1965). The recombinant human BMP-2 (rhBMP-2) in INFUSE®
Bone graft is produced in Chinese Hamster Ovary (CHO) cell lines. The API formulation
(rhBMP-2) is in the form of a lyophilized powder that has to be reconstituted with sterile
water for injection (FDA Rockville, 2014). After reconstitution the protein solution is
evenly distributed over the collagen scaffold and a period of 15-30 min is allowed for the
binding of the protein with the scaffold before placing the implant in patients (FDA
Rockville, 2014). The drug substance rhBMP-2 is generally provided as a total amount
of 12mg of protein and after reconstitution is at a final concentration of 1.5mg/mL. The
size of the carrier collagen sponges vary and are generally 1 X 2 in. or 3 X 4 in.
depending upon the size of INFUSE® Bone graft kit chosen (FDA Rockville, 2014) . The
dosage form with all its components have been photographed in Figure 4-1.
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Figure 4-1. Dosage form INFUSE® Bone graft with its components.
After reconstitution of lyophilized rhBMP-2 with sterile water and distribution over ACS a
binding time of 30-45min was allowed for effective incorporation of rhBMP-2 in ACS.

85

The bovine collagen based scaffold in INFUSE® Bone graft called Absorbable Collagen
Sponge (ACS) acts both as a carrier for BMP-2 and a supporting framework for invading
osteoclast and osteoblast cells (Geiger et al., 2003). ACS thus helps in retaining the
BMP-2 at the requisite local site of action over an extended period of time (Friess et al.,
1999; Geiger et al., 2003). Due to its biodegradable nature eventually the scaffold is
entirely replaced by new bone and there is no requirement to remove the implant with a
post-operative surgery for the patient (Geiger et al., 2003).
Osteograf-N/300:
In this current study the release of rhBMP-2 from the ACS scaffold was also compared
to its release from another natural hydroxylapatite-based scaffold called OsteografN/300. Similar to ACS, Osteograf-N/300 is also bovine derived and is a microporous
anorganic hydroxylapatite (Hakimi, 2000). It has been used as a filling material/scaffold
particularly in sinus floor elevation studies by clinicians (Froum et al., 1998). OsteografN/300 has been applied as a standalone dosage form for remodeling of bones or in
several studies in conjunction with BMP-2 to help in bone remodeling (Hakimi, 2000).
Therefore, the in-vitro release profiles of rhBMP-2 from two established scaffolds were
compared to one another. This in turn was used for establishing an In Vitro In Vivo
Relationship (IVIVR) in this study by comparison of rat in-vivo pharmacokinetic data
(obtained from literature) with biorelevant in vitro release data (FDA Rockville, 2007a;
Uludag et al., 1999a). Figure 4-2 is a photograph of Osteograf N-300 natural
hydroxyapatite carrier material.
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Figure 4-2. Dosage form Osteograf N-300 with its components.
After reconstitution of lyophilized rhBMP-2 with sterile water a binding time of 30-45min
between rhBMP-2 and natural hydroxyapatite bone graft carrier was allowed
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4.2.3 Physiological environment affecting release of rhBMP-2
from ACS

4.2.3.1 Local effects of rhBMP-2
In order to design a clinically relevant in vitro release study design an in-depth
understanding of the physiological microenvironment of the dosage form was critical.
The local and systemic exposures of rhBMP-2 during bone regeneration process were
therefore evaluated. Bone regeneration occurs in three stages. A) An inflammatory
stage B) a repair stage and finally C) the remodeling stage (Kalfas, 2001)
Stage 1 is the early inflammatory stage that encompasses the first initial hours and can
last up to a week. During this stage, the hematoma formation occurs and various
inflammatory cells like macrophages, white blood cells are attracted to the fracture site.
These cells release inflammatory molecules around the wound tissue, which are
basically signaling molecules(Chen et al., 1997). The signaling molecules attract the
mesenchymal cells, which establish the foundation for attracting the osteoprogenitor
(bone regenerating) cells (Kalfas, 2001). The nutrient material to sustain these cells at
the wound site is obtained by resorption of dead surrounding bone tissue by enzymes
like collagenases (Ma et al., 2004). Table 4-1 and Table 4-2 is a list of the crucial in vivo
and in vitro parameters affecting the release of rhBMP-2 from the collagen scaffold. The
wound or fracture microenvironment is different from the normal physiological state. It is
slightly acidic (pH of 7.1 ± 0.1) as compared to physiological pH (7.4 ± 0.2); infused with
inflammatory molecules and digesting enzymes(Hollinger and Wong, 1996).
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In an implanted collagen scaffold like ACS during stage 1, the collagenases digesting
the collagen will affect release of rhBMP-2, by causing a kind of matrix erosion. The
degradation products of collagen digestion also end up in making the wound
microenvironment more acidic and hence a decrease in physiological pH (Geiger et al.,
2003). As a result the binding of rhBMP-2 to ACS is affected and a net increase in
release of the protein from the scaffold during the stage 1/ early inflammatory stage has
been speculated. What fraction of the burst release phase observed is a) due to binding
effects of rhBMP-2 to ACS or b) is due to the changes in the wound microenvironment
is not known but is considered as a complex interplay of the above factors. During this
stage there is also increased temperature at the wound site: 1-2°C higher, which might
affect the already released protein by causing aggregation. The higher temperature for
a prolonged time of hours to a week has been speculated to affect the activity of the
protein and hence decreases the local effect of rhBMP-2 (Geiger et al., 2003). There
are also other factors like presence of serum and plasma proteins, which decrease the
binding of rhBMP-2 to the ACS thereby increasing the release.
Stage 2 is the repair stage and Stage 3 is the remodeling stage of bone healing. It is
during these stages that the vascularization process begins. During these two stages
controlled or sustained release is required unlike the burst release phase. The
osteoprogenitor cells, which have penetrated the matrix, cause differentiation of the
cells thus slower controlled release into the local environment is best suited. The
biorelevant a) in vivo and b) in vitro factors, which were considered significant in
influencing drug release from the ACS scaffold, have been summarized in Table 4-1
and Table 4-2 respectively. Several of these factors have been explored in this research
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investigation and incorporated into the in vitro release study design.

Table 4-1. Crucial in vivo biorelevant parameters affecting release of rhBMP-2.

1

Enzymes and other large molecules e.g collagenases digesting the ACS
scaffold.

2

Hematoma formation on the ACS 3-6 days after implantation.

3

Inflammatory response molecules.

4

Physiological pH.

5

Blood flow rate vascularization near the implant site.

6

Flow direction.

7

Masticatory pressure on the implant.

8

Packing density of tissues and the scaffold at the surgery site.
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Table 4-2. Crucial in vitro biorelevant parameters affecting release of rhBMP-2

1

Media pH-buffering system/capacity.

2

Osmotic pressure.

3

Media volume/Maintenance of sink conditions to maintain solubility.

4

A) Flow rate. B) Flow direction.

5

Stress application.

6

Effect of packing with hydroxyapatite/glass beads on release.

7

Effect of adding collagenase enzyme on release.

8

Membranes-biomembrane vs. artificial membranes.
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4.2.3.2 Systemic exposures of rhBMP-2
During stage 1 of the wound healing phase the site has an enhanced blood supply due
to inflammation. As a result, the rhBMP-2 molecule, which acts as a signaling molecule
for attracting the mesenchymal stem cells and osteoprogenitor cell, is carried into the
systemic circulation. To a certain degree burst release has been said to be desirable in
the initial stages of bone healing so that the signaling molecules can reach the systemic
circulation. Systemically the uptake of rhBMP-2 by organs like liver is rapid but the
residence time is less (FDA, 2014). rhBMP-2 also has rapid catabolization and
clearance. Within 24hrs approximately 92% of rhBMP-2 is recovered in urine. The peak
maximal concentration was found to be less than 0.1% of the total dosage amount. Due
to these factors, the amount of rhBMP-2 in systemic circulation should be minimal after
a typical dosing.
However, depending on the implantation site, rhBMP-2 is known to cause numerous
unwarranted local effects due to burst release such as: tumor formation, swelling (BMPs
are a member of TGF-β signaling family and hence inflammatory molecules), inability to
breathe and morbidity when used in healing of cervical regions. These side effects can
be due to the fact that rhBMP-2 is delivered at supra-physiological doses of 1.5mg/mL.
Several factors were tested while determining the dose escalation when from moving
from rats to canine to non-human primates. Factors like a) masticatory pressure in case
of sinus augmentations, b) pressure applied when the surgeon packs the sponge into
the trauma site were studied. An optimal concentration, which could withstand these
effects, was determined to be 0.8 - 2mg/mL (Uludag et al., 1999a).

92

There is a scope for improvement in the release mechanism of rhBMP-2 from the
scaffold to prevent some of the localized adverse events. The rapid systemic clearance,
short residence time and low peak concentrations offer certain advantages against the
entire body being exposed to supra-physiological doses of the molecule. The effect of
rhBMP-2 in dosage forms such as INFUSE® Bone graft at supra-physiological doses
are hence mostly limited to local bone growth and indications. Therefore, the adverse
effects of rhBMP-2 are controlled to some degree (rapid systemic clearance) and it has
been used as an ‘orthobiologic’ drug modality (local bone regeneration), since the net
therapeutic benefits outweigh the risks.
Evaluation of the biorelevant parameters affecting the release mechanism and local
release of rhBMP-2, was therefore, one of the core motivation of this research
investigation. It led us to design and develop a multi-chambered biorelevant in vitro
model/apparatus with design components allowing incorporation of clinically relevant
parameters.

4.2.4 Biorelevant media for in-vitro release studies and flow
rate implications
4.2.4.1 Characteristics of a dissolution or release media for implants
In vitro release media for biorelevant testing is a representative of the physiological fluid
conditions in the body. The medium should as closely resemble the fluid environment in
the body surrounding the dosage form as possible. Various factors which are significant
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when selecting a dissolution medium are the pH and the buffer capacity of the medium,
the composition of inorganic ions responsible for maintaining this buffer capacity, the
changes in the media components in response to temperature and its stability
particularly at physiological body temperature 37°C, the osmolality of the media, the
solubility and stability of the released drug or the dosage form in the media over the
duration of the in-vitro release study. All these factors taken into consideration while
selecting the media would enable a more predictive release/dissolution test with less
variability.
Other significant factors associated with the media are the physiological flow rate of
blood plasma or tissue fluids surrounding the dosage form. The flow rate of the fluids
surrounding the dosage form ensures the diffusion and distribution of drug in the body.
Hence, selection of a representative flow rate while designing a predictive
dissolution/release test is also a primary contributing factor towards a predictive test. A
preference is generally given towards a known composition media, which is practical
and easy to recreate for everyday use in laboratories. Various media have been
previously used in literature to characterize release of drugs from implants such as
Dulbecco's phosphate buffered saline (PBS) media for characterizing release from
PLGA scaffolds as in Kim and co-workers or release of rhBMP-2 from Poly (D-,Llactide) disks in cell culture medium with 5%FBS as in Winn and co-workers (Kim et al.,
2003; Winn et al., 1998). The core idea is to select a medium that facilitates solubility of
the drug, is itself stable for the duration of study and also supports stability of the drug
substance for a defined period of time.
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4.2.4.2 Selection of media for release study
In this study we selected a previously characterized media modified Hanks Balanced
Salts Solution to represent the blood plasma surrounding the biodegradable implant
collagen scaffold (Iyer et al., 2007). Hanks Balanced Salts Solution is a common cell
culture media that has been used in culturing osteoclasts and osteoblast cell lines to
study bone regeneration and osteogenesis (Klokkevold et al., 1996). Modified Hanks
Balanced Salts Solution (HBSS) was used as the in vitro media for the current release
studies. The HBSS was modified by removal of phenol red to prevent the components
interference in the analytical HPLC methodology. A second component sodium
bicarbonate responsible for maintaining the buffer capacity of the media when CO2 is
purged for growing cells was also removed (since we did not require purging of CO2 at
intervals). Buffer capacity of the in vitro release media was in turn maintained with
HEPES buffer. The in vitro media was prepared by addition of 9.8 g of modified HBSS
to 975 mL of deionized water and 25mL of HEPES buffer. The modified HBSS has been
previously characterized and used for in vitro release studies in Iyer et. al.,2007 for
release characterization of a naltrexone implant (Iyer et al., 2007). Sodium azide at
0.01% was used as an antimicrobial agent.
Unique properties of the selected media, which make it a good candidate for being used
in this study, are: the characterization of the medium for changes in pH and buffer
capacity with temperature. The medium was observed to show only a 1.28 fold
reduction in buffer capacity from 24°C to 56°C (Iyer et al., 2007). The net osmolality of
freshly prepared media was 281.3 mOsm and varied between 282.3 -292.3 mOsm with
changes in temperature from 38 °C – 45 °C over a period of 30 days. These values are
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within the normal plasma osmolality range of 280-295 mOsm/kg (Iyer et al., 2007;
Thompson et al., 1986).

4.2.4.3 pH requirements of biorelevant media for the study and its
significance in bone resorption, inflammation and bone
remodelling
The first step in bone regeneration is resorption and hence removal of the old dead and
decaying bones by the osteoclast cells. This is brought about by extracellular
acidification. The acidification causes dissolution of the organic and mineral constituents
of the bone and helps in the activation of various lysosomal enzymes such as carbonic
anhydrase (Baron et al., 1985). Bone regeneration with the help of ‘orthobiologics’ such
as carrier scaffolds e.g. Absorbable Collagen Sponge (ACS) and PLGA often creates a
localized

acidic

microenvironment.

This

acidic

inflammatory

osteogenic

microenvironment was studied by Kohn et. al in 2001 to investigate its effects on tissue
engineering of bone (Kohn et al., 2002). It was found that growth and differentiation of
osteogenic cells such as osteoblasts is particularly sensitive to changes in pH. Bone
resorption, regeneration and modeling are particularly dependent on the interstitial
surrounding fluid pH and tissue pH. An acidic pH supports bone resorption and a basic
pH supports regenerative activities. Since trauma sites are generally slightly acidic the
media pH was also adjusted to a pH of 7.1 ± 0.1 using 1N hydrochloric acid or 1N
sodium hydroxide.
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4.2.4.4 Flow rate selection and vascularization study of implanted
graft material
INFUSE® Bone graft application for bone healing and regeneration is an ‘orthobiologic’
approach as opposed to autografted bones. Continuous blood flow and supply to the
implant graft area are significant for the survival of the graft. The continuous blood flow
helps in carrying the neuropeptides and cytokines like bradykinins and rhBMP-2, which
eventually help in the osteo-integration of the graft material (Dimitriou et al., 2011;
Dimitriou et al., 2005). The placement of the graft in the sinus lift cavity induces acute
and chronic inflammation in the area. Inflammation is characterized by enhanced blood
flow due to vasodilation of the blood vessels surrounding the graft zone (Berggreen et
al., 2007). The dilated blood vessels are also a result of release of neuropeptides,
prostaglandins and bradykinins. Cytokines such as rhBMP-2 (which are chemo
attractant molecules) activate a chemical signal to attract osteoclast cells and
macrophages to digest the decaying surrounding bone tissues and replace with the help
of new bone forming cells called osteoblasts (Dimitriou et al., 2005). During this entire
process of bone growth acute inflammation is followed by chronic induced inflammation
(Claes et al., 2012).
Chronic inflammation persists from weeks to months (Berggreen et al., 2007). The
acute inflammation predominantly causes vasodilation and blood flow changes. Chronic
inflammation however is dominated by cellular regeneration phases in addition to flow
changes in the localized surrounding area (Berggreen et al., 2007). Normal resting
blood flow rates in the pulpal area are between 0.17- 0.19mL/min called as pulpal blood
flow (PBF)(Berggreen et al., 2007). During inflammation vasodilation can lead to a
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200% increase in PBF and in turn vascular permeability for interchange of large
molecules with the surrounding blood and interstitial fluid (Berggreen et al., 2007). The
vasodilation is advantageous not only to deliver osteoinductive molecules to the site of
regeneration but also to help in carrying away the heat generated (due to inflammation)
and decaying by products of the regenerating bone (Dimitriou et al., 2011).
A detailed study in Solar et. al. showed that implanted grafts during sinus lifts and
augmentations require blood supply from three major blood vessels: a) the vessels or
blood flow to the schneiderian membrane (the lining of the maxillary sinus cavity); b)the
posterior superior alveolar artery (PSAA) and the c) Infra Orbital Artery (IOA) (Solar et
al., 1999). The PSAA also supplies the growing bone and the periosteal lining of the
bone (Solar et al., 1999) and the schneiderian membrane. The measured net blood
perfusion rate of the schneiderian membrane was shown to be between 0.09mL/min0.99mL/min in a study in different animal models (Kumlien and Schiratzki, 1985).
Hence, a flow rate of 0.8- 0.9 mL/min was selected for the biorelevant media in the
designed model. This would be representative of the physiological flow associated with
inflammation in the graft area at different stages of healing. A flow rate of 0.8- 0.9
mL/min would also ensure proper mixing of the drug substance rhBMP-2, with the low
flow peristaltic pumps in the novel biorelevant in vitro model. A schematic
representation of the blood vessels supplying the maxillary sinus cavity has been shown
in Figure 4-3.
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Figure 4-3. A schematic representation of the blood vessels supplying the maxillary
sinus cavity during sinus lift and augmentation surgeries.
This picture has been modified from Solar et. al. (Solar et al., 1999)
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4.2.5 Apparatuses for in-vitro release study
4.2.5.1 Sample and separate experimental set up
As mentioned previously in Chapter 1 of this document sample and separate studies
help in establishing a baseline for in vitro release tests. Although due to lack of design
and vessel hydrodynamics, they might not be able to simulate many biorelevant
parameters (flow rates and directionality of physiological fluid, mixing) they can serve as
an essential tool in observing the baseline performance of the dosage form. Many of the
significant biorelevant parameters such as temperature, pH can be included in such
experimental set ups. In our current study sample and separate experiments were
performed in phosphate buffered saline (PBS). 200µg of rhBMP-2 was loaded onto 0.5
X 0.67 in of the absorbable collagen sponge scaffold at rhBMP-2 concentration of
1.5mg/mL. Each sample and separate tube had 5mL of media. Replicates of the tubes
were prepared including blank controls (collagen sponge with no rhBMP-2). The entire
media was replaced at 0.5hr, 1hr, 4hr and 6hr followed by once daily after the first day
for up to 15 days. The tubes were incubated at 37°C. The pH of the medium was
adjusted to 7.1 ± 0.1. The samples were analyzed using Quantikine ELISA kit (R & D
Systems, USA). The linear dynamic range of the assay was from 62.5pg/mL2000pg/mL. A sandwich ELISA was performed according to the kits manual and optical
density measurements were recorded with BioTek ELISA microplate reader at 450nm.
Background readings for the plate were measured and subtracted at 540nm. The
amount of rhBMP-2 released in the in vitro study was plotted against time in days. A
pictorial representation of the sample and separate set up has been shown in Figure 44. Table 4-3 summarizes the experimental conditions of the sample and separate set
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Figure 4-4. A pictorial representation of the sample and separate set up at 37°C.
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up and the biorelevant parameters incorporated while performing the test.

4.2.5.2 USP-IV Flow through cell experimental set up
In our current study of rhBMP-2 release from ACS scaffold (INFUSE® Bone graft) a
modified flow through cell experimental set up was used after the initial sample and
separate methodology. The modified USP IV flow through apparatus consisted of two
conical glass cells of length 8.5cm each. Two Teflon fittings are present on the lower
and upper end of size 4.5 and 1.5 cm respectively. The net volume of the two-half glass
cell (clamped with o-rings and a stainless-steel clamp to render it leak proof) was 7.5 –
8 mL. An additional reservoir held 7.5ml of media and was used to complete the set up.
Total media volume was 15mL. Two such USP-IV flow through cells were mounted on
each brass stand to replicate the experiments (n=6 total experiments were performed).
Glass beads served multiple functions: In addition to providing laminar flow within the
apparatus, the beads also acted as a surrogate for simulating tissue packing and held
the floating collagen sponge dosage form in position. Protein low bind cellulose acetate
membranes were used to hold the glass beads and dosage form in the cell. Two kinds
of media were tested using this experimental set up: traditionally used phosphate
buffered saline (PBS) and biorelevant modified hank’s balanced salts solution (HBSS)
both monitored at pH 7.1 ± 0.1 over the course of release study. A pictorial
representation of the USP-IV flow through experimental set up has been shown in
Figure 4-5. Table 4-4 summarizes the experimental conditions of the USP-IV flow
through cell set up and the biorelevant parameters incorporated while performing the
test.
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Figure 4-5. A pictorial representation of the USP-IV flow through set up.
Two halves of the cells were clamped together. Each brass stand can mount two flow
through cell. Three such settings comprising of six flow through cells were used.
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Table 4-3. Experimental conditions for sample and separate study design
Factors evaluated
1. Biorelevant factors
2. Temperature
3. Media
4. Scaffold size
5. Dosage amount
6. rhBMP-2
concentration
7. pH
8. Volume (mL)
9. Sampling frequency
10. Sampling volume

Values
Temperature, pH
37°
PBS
0.5 X 0.67 in.
200ug
1.5mg/mL
7.1 ± 0.1 (Biorelevant)
5
30min, 60min, 4hr, 6hr,once daily for up to
30days.
5mL

Table 4-4. Experimental conditions for USP-IV study design
Factors evaluated
1. Biorelevant factors
2. Temperature
3. Media
4. Scaffold size
5. Dosage amount
6. rhBMP-2
concentration
7. pH
8. Volume (mL)
9. Sampling frequency
10. Sampling volume

Dosage form
component
rhBMP-2
ACS

Values
Temperature, pH, glass beads, membrane
37°C
PBS, HBSS
0.5 X 0.67 in.; 1 X 2
200 µg, 700 µg
1.5mg/mL
7.1 ± 0.1
15 mL
30min, 60min, 4hr, 6hr,once daily for up to
30days.
1 mL

Positive
Control

Negative
Control

(n=3)
+
+

(n=3)
+
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4.2.5.3 Biorelevant In Vitro Drug Release (BIVDR) model

Design of the BIVDR model:
The in house designed and constructed biorelevant in vitro drug release (BIVDR) model
has been represented in Figure 4-6 and Figure 4-7. The model design consists of three
main compartments: an outer cylindrical bone regeneration chamber called BRC, a
centrally located cylindrical core compartment housed inside the BRC called bone
packing chamber or BPC and an optional sinus chamber called SC which can be used
in case of extra volume requirements or the BRC can simply be capped off in case of
smaller volume parenteral release testing requirements. The central donor compartment
BPC opens into BRC on either side and is separated physically from BRC using
membranes selected according to the requirements of the experiment. The membranes
are screwed in position with the help of size 0 medical grade stainless steel screws, orings and a thin round donut shaped polycarbonate frame. The flow ports in each
chamber are positioned horizontally and flow directionality is parallel in all the
chambers. Additional flow ports have also been placed perpendicular to the
compartment. They can be capped off or depending upon the needs of the experiment
can be kept open (for perpendicular flow directionality, for an increased release rate for
a dosage form or for turbulent flow).
Three- way sampling/flow valves were provided in all compartments (BRC, BPC and
SC) for regular sample collection and regulating flow directionality. The BPC and SC
have one pair of flow ports whereas the BRC has two sets of flow ports. Each pair of
flow port in the BRC is positioned a few millimeters above and below the centrally
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located core compartment BPC to allow for proper mixing of fluids and drug substance
released from the donor compartment (BPC). The centrally located BPC along with the
tubings in a closed loop mode has a net volume of 2.6 mL. The net volume of fluid in the
BRC with the tubings is 8.9 mL. The additive volume of both the compartments
(BPC+BRC) with the connecting tubings amounts to 11.5mL. If the sinus chamber is
used it adds an additional 2.5mL to the model. The schematic representation of the
complete BIVDR model and the experimental set up has been shown in Figure 4-6. The
actual BIVDR model has been photographed in Figure 4-7.
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Figure 4-6. A schematic representation of the biorelevant in vitro drug release (BIVDR)
model experimental set up with its components: peristaltic pump, tubing connectors and
three-way sampling valves for circulation in a closed loop configuration.
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Figure 4-7. A pictorial representation of the fully constructed biorelevant in vitro drug
release (BIVDR) model.
A) Top view of the model showing both the Bone Packing Chamber (BPC) and Bone
Regeneration Chamber (BRC), B) Full lateral view of the model with all the three
chambers: BPC, BRC and Sinus Chamber (SC). If SC is not in use the model can be
capped off to use only the BPC and BRC for low volume release requirements. C) Top
view with screwed in cover/cap of the model (note: the cap has an additional flow port
for perpendicular flow if required) D) Top cross sectional view of the bottom SC.
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4.2.5.4 Biorelevant In Vitro Drug Release (BIVDR) model experimental
set up

A) Arrangement and functionality of the chambers: Bone packing chamber (BPC) and
Bone regeneration chamber (BRC)
The central core compartment (BPC) acts as the donor compartment where the dosage
form is placed. The BPC is used for simulating the tissue chamber where clinicians pack
the implant carrier scaffold as shown in Figure 4-3. It can be a) completely packed with
the carrier material e.g hydroxyapatite/ACS or b) partially packed with the remaining
space filled up with media. During a sinus lift surgery the clinician normally creates a
lateral window by incision, of approximately 13mm from the bony alveolar ridge of the
sinus lift cavity (Rosano et al., 2011). This size of incision is for general sizes of
implants of 11-13mm such as INFUSE® Bone graft, absorbable collagen carrier sponge
Therefore, a central compartment with a height of 11-13mm was selected; with a net
volume of 2-3mL representing the central cavity during sinus lifts and sinus
augmentation surgeries.
In experimental set ups where the bone packing chamber (BPC) is completely packed
with filler or carrier graft material and no release media, the release media is found only
in the surrounding bone regeneration chamber (BRC). Release samples then need to
be collected only from the BRC and would represent the local release. If complete filling
of the chamber is not required such as smaller size of carrier scaffolds, liposomes or
microspheres the central BPC can have biorelevant media circulating through it. In such
a case release samples collected from the BPC and additionally from BRC in totality
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would represent the drug released at a sampling time point. In dosage forms such as
ocular implants drug biodistribution occurs into multiple tissue chambers with different
composition and osmolality of physiological fluids in each chamber (Bochot and Fattal,
2012). To represent physiological drug biodistribution in multiple tissue chambers two
different compositions of media can be circulated through the compartments BPC and
BRC. This would represent two different physiological fluid microenvironments. In our
current research study since we were primarily concerned with the local release of
rhBMP-2, hence, we used a single media in both the chambers BPC and BRC. Two
peristaltic pumps circulate media within each compartment. Each of the pump is in a
closed loop configuration i.e BRC circulates media in its own closed loop separate from
the BPC. Each closed loop configuration has its own three-way flow valve, which is
used during sampling at regular intervals. During sampling the peristaltic pumps are
switched off for about 2 min to allow for the collection of the release samples. The
volume lost during sampling is replaced into the BIVDR model using the same threeway flow valve with a graduated plunger syringe separately into each chamber.
The core compartment BPC was enclosed with membranes of low protein bind nature
e.g. regenerated cellulose, cellulose acetate, polycarbonate membranes ensuring
negligible adsorption and continuous permeation of rhBMP-2. The membranes had a
pore size of 0.45 µm. The net dimensions of the rhBMP-2 homodimer are 70 Å × 35 Å ×
30 Å (Scheufler et al., 1999). In vivo pore diameter for pores found on the endothelial
capillary vessels is 24 Å (Pappenheimer et al., 1951). Therefore, the porosity of the
membranes used in vitro are in the order of 106 times the size of both: a) the rhBMP-2
molecule and b) in vivo pores found on the capillary walls. It can be safely stated that

110

the in vitro porosity of the membranes will not be limiting factor to the diffusion of the
rhBMP-2 molecule. If required two variable flow rates such as mucosal flow rate and
periosteal flow rates can be simulated in the BPC and BRC. However, in our present
study these flow rates are almost similar between 0.8 - 0.9 mL/min (Berggreen et al.,
2007; Solar et al., 1999). Therefore, the flow rates of all the chambers in our study were
initially maintained at 0.8 - 0.9 mL/min as a starting point.
B) Flow directionality selection between chambers:
The flow directionality was controlled with the help of peristaltic pumps, three-way flow
valves and connector fittings obtained from VDR, Cellmax and Spectrum laboratories
respectively. These are special biocompatible flow valves to keep a tubing port open or
closed. They are often used in cell culture experimental set ups to regulate the
directionality of flow and help in easy sampling. Although all the chambers have inlet
and outlet valves the valves were operated in combination, so as to simulate
combinations of flow directionality. Flow directionality experiments would help us
explore the affects of in vitro flow direction in the BIVDR model on drug release at a
specific flow rate. A pictorial representation of the flow directionality choices have been
shown in the Figure 4-8. The red line represents the flow direction of the media between
the two compartments
i)

Figure 4-8 (Module A):

represents the situation in which the flow is

maintained in parallel in both the chambers (BPC +BRC).
ii)

Figure 4-8 (Module B): represents a situation in which the flow is maintained
only in BRC and BPC has no flow. This situation can be used when the entire
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central BPC needs to be packed up with the carrier/dosage form e.g.
natural/synthetic hydroxyapatite carriers for rhBMP-2 in sinus augmentation
lift surgeries. Alternatively, it can also be used in a situation where we require
some degree of segregation of the media and the carrier yet free exchange of
drug is required e.g. microspheres, liposomes, nanoparticulate implants.
iii)

Figure 4-8 (Module C): represents a ‘Z’ patterned flow in which the flow in
BPC is turned off and the flow in BRC, of the diagonal ends of the ports is
maintained. The flow in BRC therefore indirectly drives the flow through BPC.
Such flow directionality would help simulate a mixture of laminar and turbulent
flow in the BIVDR model and can be used uniquely to offer flexibility to
increase or decrease the release of drug substance from a dosage form in a
single model.

A paired samples t test was conducted with pairwise alignment for each time point to
compare the flow in (BPC + BRC) with a) flow only in BRC and b) Z patterned flow in
BRC, at a significance level of α = 0.05. Results were reported as a t test value with
degrees of freedom (t(df)) and p values respectively. To summarize, the modular design
of the novel biorelevant model was intended to better simulate in vivo physiological
conditions like intra osseous vascularity, effect of tissue packing on the dosage form,
change in pH and osmolarity in the surrounding environment and relate it to the release
of the active ingredient from the dosage form. The combination of multiple flow
directionality can also be used in the future if this model’s application is extended further
to other complex non-oral dosage forms such as liposomes, microspheres. Better
incorporation of the in vivo conditions will enable us to better understand and predict the

112

bio-performance of the dosage form making the model more suited for clinical
predictions of implants and novel dosage forms.

Figure 4-8. Flow directionality options between chambers in the BIVDR model.
BRC: Bone regeneration chamber; BPC: Bone packing chamber. The red solid line
indicates the direction of flow of media.
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4.2.5.5 Experiments for selection of low protein-adsorption polymer
material for construction of body of the in vitro model
In vitro release experiments using USP-IV glass flow through cell showed considerable
protein adsorption to the body of the model and has been discussed in-depth in the
results section of this chapter. To prevent similar losses in drug substance due to
protein adsorption, the polymer selection experiments for the body of the BIVDR model
were performed. Polymer materials which are traditionally known in literature as having
low protein adsorption properties such as a) poly ether ether ketone (PEEK) used in
making of HPLC consumables, b) polycarbonate (PC) used in medical grade
equipments and IV bags, and c) poly tetra fluoro ethylene (PTFE) were acquired from
the vendor. They were neatly cut into small pieces of 1 X 1 X 1 cm3 volume. Each of
these pieces were immersed in 4mL of rhBMP-2 solution of concentration 10 µg/mL in
modified HBSS and placed in nalgene tubes for incubation at 37°C. The control tube
consisted of the protein rhBMP-2 solution but with no polymer block in it. 250 µL of
sample was removed at 30 min., 24hr. and 72 hr. respectively. The samples were
analyzed using an already validated HPLC-UV method as described in Chapter 3 of this
thesis. The rhBMP-2 recovery percent was recorded and plotted against the time.
ANOVA with Dunnett’s multiple comparisons test was used for all purposes of statistical
comparisons between different samples. The polymer material with minimal protein
adsorption and maximal rhBMP-2 recovery percent that was also compatible in the
desired working pH range of 6-8 was selected for the construction of the body of the
model.
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4.2.5.6 Selection of low protein-adsorption membranes
Low protein adsorption membranes were selected from vendors. Five such membranes
which are traditionally known to be less interactive with proteins were: a) regenerated
cellulose (RC) b) cellulose acetate (CA) c) poly ether ether sulfone (PES) d) etched
polycarbonate (PC) and e) poly tetra fluoro ethylene (PTFE). Porosity of all the above
membranes was 0.45µm. Table 4-5 is a summary showing the characteristics of the
various membranes selected, their hydrophilic and hydrophobic nature to determine
compatibility with the biorelevant media used, and their protein adsorption properties as
known in literature or from information collected mostly from various vendor sites. The
membranes were cut into pieces of 4cm2 each, and incubated with rhBMP-2 solution at
a concentration of 10 µg/mL at 37°C. Total volume of solution in each tube was 3.5ml.
250 µL of sample was withdrawn at 30 min. and 24 hr. to observe the adsorption of the
rhBMP-2 to the membrane. 24 hr. was considered as the end point for the equilibration
of the membranes with the rhBMP-2 solution. Control tube consisted of rhBMP-2
solution but without any membrane. The samples were normalized at each time point
with respect to the control before calculating the recovery percent of rhBMP-2 in the
respective solution. ANOVA with Dunnett’s multiple comparisons was used for the
purposes of statistical comparison. The top three membranes with minimal protein
adsorption and maximal recovery at required pH of 6-8 were selected for incorporation
into the model.
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Table 4-5. Characteristics of different membrane types for incorporation into BIVDR
model
Type of Membrane

Nature of Membrane

1. Regenerated cellulose
(RC)

Hydrophilic membrane.

2. Cellulose acetate
(CA)

Hydrophilic membrane.

Limited solvent resistance.
Very low protein binding
capacity, which makes it a
good choice for protein
applications.

3. Polyethersulfone
(PES)

Hydrophilic membrane.

Good solvent compatibility:
aqueous and organic
solvents. Low protein
binding.

4. Polycarbonate
(PC)

Hydrophilic membrane.

Extremely thin
polycarbonate film, with a
very narrow pore size
distribution suitable for
aqueous and some organic
solvents

5. Poly tetra fluoro ethylene
(PTFE)

Hydrophobic membrane

Very low protein adsorption.
Compatibility with organic
solvents and can be also
used with aqueous solvents
but only after considerable
initial wetting with organc
solvents.
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Protein binding capacity
and compatibility with
solvents
Compatible with HPLC
solvents. Very low protein
binding capacity, which
makes it a good choice for
protein recovery
applications. Suitable for
use with either aqueous
solutions or organic
solvents

4.2.5.7 Protein adsorption studies on the biorelevant model
experimental set up

Adsorption of rhBMP-2 to the model:
Before incorporation of the membranes into the model it was essential to estimate the
rhBMP-2 adsorption just to the BIVDR model experimental set up without the presence
of the membranes. Analysis of the rhBMP-2 adsorption to the BIVDR model, with the
introduction of membranes into the model would then elucidate if the adsorption effect
was composite or a net additive effect was observed. For this the complete BIVDR
model experimental set up with its components: the tubing and the pump assembly
were arranged in a closed loop configuration. rhBMP-2 solution in media was circulated
at a concentration of 10 µg/mL for a period of 24 hrs at a flow rate of 0.8 – 0.9 mL/min.
Samples were collected at 30 min., 2, 5, 18, and 24 hr respectively, from the BRC
chamber sampling port. The sampling time points were kept as close/similar as possible
to the actual in vivo and planned in vitro sample collection time points. Control consisted
of an aliquot of same rhBMP-2 solution incubated at 37°C in a nalgene tube. A paired
samples t test was conducted to observed the recovery percentage difference between
the control and BIVDR model at a significance level of α=0.05.
Adsorption of rhBMP-2 to the model with membranes included:
The next step was to introduce the top two low protein adsorption membranes into the
model and observe the recovery percentage of rhBMP-2. rhBMP-2 solution in media
was placed in the BPC at a concentration of 15 µg/mL for a period of 24 hrs at a flow
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rate of 0.8 – 0.9 mL/min. Samples were collected at 0hr, 0.25hr, 6hr and 24 hr from the
BPC and BRC chamber sampling port. The net (BPC + BRC) percentage recovery of
rhBMP-2 from the model was recorded and a membrane with better recovery,
performance and lesser variability was selected for the in vitro release study.

4.2.6 Sample Analysis
In vitro release test samples were analyzed using a previously validated HPLC method
described in Chapter 3 of this thesis. The dynamic range of the assay was from 0.5
µg/mL to 100 µg/mL. Minimal sample preparation was required and the assay helped in
high throughput release sample analysis. Release samples collected were generally
analyzed on the same day but the assay was also validated with regards to freeze-thaw
stability, benchtop stability, autosampler stability at 4°C and forced degradation analysis
for the presence and detection of degradation products in the sample.

4.2.7 Evaluation of In Vitro Relationship (IVR)
The dosage amount for rhBMP-2 was maintained at a constant concentration of
1.5mg/mL and was distributed uniformly onto the carrier scaffolds ACS and Osteograf
N-300. The release studies were carried in the novel biorelevant model until
approximately 80 % of dose was released from the carriers (Pillay and Fassihi, 1998;
Shen and Burgess, 2015; Zolnik and Burgess, 2008). The cumulative in vitro release
profiles from each of the formulations were compared to their existing in vivo rat data.
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An In Vitro Relationship (IVR) was evaluated to observe if the cumulative release
profiles are discriminatory amongst the carrier variants. It has been observed that a
difference in the carrier scaffold influences the release profile and bone score of rhBMP2 to a considerable extent (Sigurdsson et al., 1996). The release of rhBMP-2 from its
scaffold depends upon the mechanical properties of the scaffold, the adherence level of
the protein to the scaffold, which is the binding affinity of the protein to the scaffold, and
the degradation rate of the scaffold in its environment (faster degrading scaffolds will
release the protein sooner into the environment) which may or may not be a desirable
property for the dosage form depending upon the application requirements.

4.2.7.1 Time scaling and Levy Plots
Time scaling and shifting are effective tools in developing a successful IVIVC/IVIVR/IVR
for complex parenteral and extended release dosage forms. The primary purpose of
time scaling is to rectify the rate between in vivo absorption/release and in vitro
dissolution/release (Brockmeier, 1983). A time lag can be observed under two
conditions while comparing the in vitro and in vivo data. A lag can be observed in the in
vivo data due to delay in absorption (e.g. in case of immediate release dosage forms) or
delay in release (e.g. many extended release parenteral dosage forms). This type of
delay in in vivo data is generally observed as a negative intercept on the Y-axis. The
other case of time lag is observed when a dosage form shows a delay with in vitro
dissolution but there is in vivo absorption/release data during the period. This can occur
due to an initial rapid burst release phase in the complex inflammatory in vivo
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microenvironment due to plasma proteins, enzymes, collagenases (e.g. in special
dosage forms such as liposomes, PLGA microspheres or carrier based scaffolds such
as INFUSE® Bone Graft). This delay is generally observed as a positive intercept on the
Y-axis. This lag in time, which, occurs, in either case is called as time lag or time
shifting. Correction of time lag and rates of in vivo and in vitro release is commonly done
by plotting Levy plots for normalization of data. A levy plot is created by plotting the in
vitro dissolution/release time of certain specific percentages on the X-axis (e.g. time
taken to release 10%, 20%, 30% of the drug substance) vs. the time taken in vivo for
absorption/release of similar percentages of drug. A linear levy plot touching zero
indicates similar rates of in vitro and in vivo dissolution/release. If the rates in vitro and
in vivo are different, intercepts on the X and Y-axis might be observed as described
above. Levy plots can be plotted more accurately by frequent sampling time points in in
vitro dissolution/release data to allow for more accurate prediction of a relationship.
Once a levy plot has been plotted and a time scaling factor is obtained this can then be
applied to the normalization of data and in vitro and in vivo release data on the same
time scale can be plotted against one another to study and establish a relationship
(IVIVR/IVR).

4.2.7.2 Similarity (f2) and difference (f1) factors as parameters to
establish ‘discriminatory’ nature of a release profile
Special dosage forms such, as extended controlled release parenterals e.g. nano
particles, liposomes or carrier based implants often require establishing an in vitro
relationship (IVR) instead of an IVIVC. For release / dissolution tests in addition to
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establishing a release profile and an IVIVR, it is also crucial to show that the method is
suitably discriminatory between formulations. Release rate profiles can generally be
analyzed using model dependent approach, model independent approach (f1 and f2) or
statistical analysis such as ANOVA (one way analysis of variance) and MANOVA
(multivariate analysis of variance). The difference factor (f1) and similarity factor (f2)
have often been used for establishing discriminatory nature of a dissolution/release test
between its formulations (Moore and Flanner, 1996; Zolnik and Burgess, 2008). The
similarity factor f2 and difference factor f1 provide quantitative measurements of the
release profiles between the test and reference product. As the name suggests f1
measures the difference at each time point between the reference and the test. A value
of zero for f1 suggests no difference in the release profiles and a value of 100 would
suggest completely different releases profiles. According to FDA guidelines a value of
f1<15 is required for bioequivalence (Shah et al., 1997). Hence a value of f1>15
suggests discriminatory profile. f2 (similarity factor) is measured between 0 and 100 and
measures the similarity of the release profiles (Shah et al., 1998). It is a transformation
achieved by logarithmic measures of the difference between the reference and test. A
value of ‘0’ for f2 would indicate completely dissimilar profiles and a value of ‘100’ would
indicate a completely similar release profile between the test and the reference
formulations. These factors generally give an idea about the point-to-point percent
predictive error in the release/dissolution between test and reference product or two
different formulations. FDA guidelines require values of f2 > 50 for similarity. Hence,
values of f2 < 50 indicate discriminatory release tests. Care has to be taken to not apply
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f1 and f2 factors to the same formulation under varying release test conditions. The
equations for f1 and f2 factors have been reported below (Pillay and Fassihi, 1998).

𝒇𝟏 =
𝒇𝟐 = 𝟓𝟎 ∗ 𝒍𝒐𝒈

𝒏
𝒕!𝟏 𝑹𝒕 ! 𝑻𝒕
𝒏
𝒕!𝟏 𝑹𝒕

𝟏! 𝟏 𝒏

𝒏
𝒕!𝟏

∗ 𝟏𝟎
𝑹𝒕 !𝑻𝒕 𝟐

!𝟎.𝟓

∗ 𝟏𝟎𝟎

In the above equations Rt is the cumulative percent release for the reference product or
formulation, which in current case is INFUSE® Bone graft and Tt, is the test product,
which in this research study is Osteograf N-300.The objective of our study was
therefore, to design and develop a biorelevant model and show that it is discriminatory
between formulations of INFUSE® Bone Graft and Osteograf N 300.

4.3 Results and Discussion
4.3.1

Sample and separate and USP flow through cell
release profiles

For the sample and separate model the initial release of BMP-2 from ACS scaffold was
observed to be 45.21 ± 2.53% within a time of 5 days with a burst release profile of
15.04 ±2.09 % over the first 24 hours. A total release of 58.89± 4.97 % over 30 days
was finally observed. The Flow Through Cell also showed a similar burst profile as the
sample and separate of 15.23 ± 2.99% over the first 24hours for PBS and biorelevant
media studies but the difference being, this ~ 15% burst release was achieved within
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90min of starting of the experiment. Negligible release was observed in this model for
the remaining 24hrs. The release almost reached an apparent asymptote over the next
24hrs. This can be due to two suspected reasons: 1) a uniform flow rate was not
sufficient to maintain the controlled release rate in the USP-IV model after the initial
burst release phase (possibly because of factors like packaging with glass beads of the
dosage form- floating ACS scaffold) or 2) The released protein rhBMP-2 adheres to the
glass USP-IV flow cell and to the glass beads. Upon further investigation it was found
that similar problem has been reported in literature by investigators dealing with in vitro
release testing of proteins (Xu et al., 2012). Therefore, the approach would be to study
the release of the implant system in an eppendorf/protein low bind tubes and compare
the release with that in a glass tube. The release can be studied over a period of 24hrs
to 5 days for these adsorption studies. If the glass container gives substantially lower
release profiles as compared to the eppendorf/protein low bind tube under the same
minimal experimental conditions, it can be stated that the low release rate in the USP-IV
cell is because of protein adsorption to USP-IV glass surface. From our stability analysis
in Chapter 3 we already know that the stability of rhBMP-2 in modified HBSS media is
>90% over 24 hrs.
In conclusion, the a) sample and separate and b) the USP-IV in vitro profiles were
distinctly different from the in vivo burst release profile. In the in vivo rat system the loss
of ~15% occurred only after the 2nd day. Comparison of the amount retained at the end
of 5-day period also showed differences in the percentage yet to be released. The
sample and separate model had approximately 55% retained; USP-IV for PBS and
modified HBSS retained approximately 85%. Thus, it was observed that these in vitro
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models did not compare to the in vivo profile. The sample and separate and USP-IV
model percentage cumulative drug release profiles have been represented in Figure 421 later in this chapter (in conjunction with BIVDR model data).

4.3.2 BIVDR Model
4.3.2.1 Model body polymer selection
Adsorption of rhBMP-2 to three different polymer materials poly ether ether ketone
(PEEK); Poly tetra fluoro ethylene (PTFE) and Polycarbonate was studied at 37°C.
Control set up constituted (no polymer cube incubated with rhBMP-2 solution). At
30min. no significant adsorption was observed to either of the polymer materials.
ANOVA with Dunnett’s multiple comparisons test was used for the purposes of
statistical comparisons. At the end of 72hrs. the PEEK tube showed a recovery % of
98.65 ± 2.26 %; PTFE 61.89 ± 0.47 % and polycarbonate a net recovery % of 103.95 ±
1.52 %. This revealed PTFE had the maximum adsorption to rhBMP-2 and hence the
lowest recovery percentage. Therefore, based on the rhBMP-2 protein adsorption
results polycarbonate (PC) polymer was selected as the material of choice for the
construction of the body of the model. The results of the polymer for model body
creation have been plotted as a bar graph in Figure 4-9. A one-way ANOVA with
Dunnett’s multiple comparisons test was performed at a significance level α=0.05. The
specific time points (30min., 24hr and 72 hr) for each of the corresponding incubated
samples with the polymer were compared with their control (without polymer) at same
day of incubation to observe if the means were significantly different. At the end of the
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Figure 4-9. Selection of BIVDR body material: adsorption studies of rhBMP-2 to a)
Polycarbonate b) PTFE c) PEEK.
All statistical comparison between samples have been made with ANOVA Dunnett’s
multiple comparisons test. p <.005(**); p <.00005(****).
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72hr. incubation, the mean recovery percentage for rhBMP-2 was not significantly
different for PEEK (p=0.8454) and PC (p=0.3146); however, for PTFE samples the
mean percentage recovery was significantly different (p=0.0001) from the control
sample.

4.3.2.2 Membrane selection
Membrane selection experiments showed similar results as model body polymer
experiments but with the exception that significant differences were observed in rhBMP2 recovery after 30min. of incubation. Regenerated cellulose (RC) membrane had a
recovery percent of 81.22 ± 0.68; cellulose acetate (CA) of 83.26 ± 2.86; poly ether
ether sulfone (PES) of 43.14 ± 1.01; polycarbonate (PC) of 73.91 ± 1.85 and poly
tetrafluoro ethylene (PTFE) of 74.08 ± 3.40. At the end of 24hrs RC showed a recovery
percent of 81.22 ± 0.68; CA a recovery percent of 83.26 ± 2.86; PES a recovery percent
of 43.14 ± 1.01; PC a recovery percent of 73.91 ± 1.85 and finally PTFE a recovery
percent of 74.08 ± 3.40. Based on the above results RC, CA and PC/PTFE showed
minimal adsorption to rhBMP-2 solution. However, PTFE is a hydrophobic membrane
and since free exchange between the compartments of BIVDR model i.e. BRC (outer
compartment) and BPC (inner compartment) is desired in the buffer media (HBSS),
which has no organic components to it PTFE was eliminated as an option. PC
membrane showed comparable results but was extremely thin and fragile, and difficult
to handle. Since the BIVDR model required the membrane to be screwed in a round
circumference using size 0 medical grade screws, some degree of robustness was
required of the membranes to prevent tear, damage or perforation to the membrane
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while setting up the in vitro model for testing. For this reason PC was also not selected
as a choice. Regenerated cellulose (RC) and cellulose acetate (CA) membranes were
selected for the experiments with the BIVDR model. The results of the membrane
selection experiments have been plotted as a bar graph in Figure 4-10.

4.3.2.3 Protein adsorption to the BIVDR model and model
components and recovery
Before beginning the in vitro release experiments in the BIVDR model it was important
to assess the rhBMP-2 loss due to adsorption, to the various components of the
experimental set up (BIVDR model, pump tubiings and flow valves). This was carried
out by a sequential experimental design plan. The schematic of the design plan has
been shown in a flow chart in Figure 4-11. Since membrane was an external component
added to the BIVDR model the rhBMP-2 recovery was first assessed in the model a)
without the membrane followed by b) with the membranes, introduction of the two
membranes: regenerated cellulose (RC) and cellulose acetate (CA). Samples were
collected at regular intervals of 30 min., 2hr, 5hr, 18hr,and 24hr respectively.
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Figure 4-10. Membrane selection for BIVDR model. Study of rhBMP-2 adsorption to
five different membranes
a) Regenerated cellulose b) Cellulose acetate c) Poly Ether Ether Sulfone d)
Polycarbonate e) Poly tetra fluoro ethylene. All statistical comparison between samples
have been made with ANOVA Dunnett’s multiple comparisons test. p <.005(**); p
<.0005(***).
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Figure 4-11. Flowchart summarizing BIVDR model experimental study design.
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The rhBMP-2 recovery in the model with all the components of the experimental set up
were recorded to be 94.053 ± 2.910 after 30 min., 91.101 ± 1.401 after 2hr., 91.495 ±
0.707 after 5 hr., 87.092 ± 1.414 after 18hr., and 87.116 ± 1.181 after 24 hr.
respectively. A paired samples t test was conducted with respect to the controls
incubated in an eppendorf tube incubated for the same duration of time to observe the
difference between the control (rhBMP-2 solution not in BIVDR model set up) and the
recovery percent in the BIVDR model at a significance level of α=0.05. A significant
difference was observed t(4)= 7.272 with a p value of 0.0019. The bar graph for the
percent recovery of rhBMP-2 vs. time has been shown in Figure 4-12.

The next step was to study rhBMP-2 recovery percent with the introduction of the
membranes in the model set up. rhBMP-2 solution was placed in the core compartment
(BPC) and modified HBSS media was circulated in outer compartment (BRC) at a
concentration of 20 µg/mL. Samples were collected at 0hr., 0.25hr.,6hr. and 24hr.
respectively. The total recovery percent was calculated to be 94.58 at 0.25 hr., 90.79 at
6hr., and 84.31 at 24 hr. with RC membrane. The individual recovery percent in each
chamber and total mean recovery percent (BPC+BRC) for the RC membrane has been
shown in Figure 4-13 and Figure 4-14 respectively. The experiments were repeated with
CA membrane to observe the recovery percent in the model. These were recorded to
be 69.92 at 0.25 hr., 60.19 at 6 hr., and 86.23 at 24 hr. respectively. The individual
recovery percent in each compartment of the BIVDR model and the total percent
recovery (BPC+BRC) for CA membrane have been shown in Figure 4-15 and Figure 416 respectively.
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Figure 4-12. rhBMP-2 recovery percentage in BIVDR model experimental set up with
pump tubings and flow valves.
Note: The membranes have not been introduced at this stage. The rhBMP-2 solution is
(20 µg/mL) circulated in the model at a flow rate of 0.8 – 0.9 mL/min.
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Figure 4-13. rhBMP-2 recovery percentage in each chamber of the model core Bone
Packing Chamber (BPC) and surrounding Bone Regenerating Chamber (BRC) with the
introduction of regenerated cellulose membrane into the experimental set up.
Note: the rhBMP-2 solution (20 µg/mL) was placed in the core compartment BPC.
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Figure 4-14. Net recovery (BPC+BRC) of rhBMP-2 in the BIVDR model experimental
set up with the introduction of regenerated cellulose membrane.

133

Figure 4-15. rhBMP-2 recovery percentage in each chamber of the model core Bone
Packing Chamber (BPC) and surrounding Bone Regenerating Chamber (BRC) with the
introduction of cellulose acetate membrane into the experimental set up.
Note: the rhBMP-2 solution (10µg/mL) was placed in the core compartment BPC.
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Figure 4-16. . Net recovery (BPC+BRC) of rhBMP-2 in the BIVDR model experimental
set up with the introduction of cellulose acetate membrane.
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In an attempt to increase the recovery percentage extremely low concentration of the
surfactant polysorbate 80 (already present in the rhBMP-2 lyophilized formulation at
0.01%) was added to the media at 0.001% and the recovery was again tested with the
RC and CA membranes. For the analytical test methodology (HPLC-UV) the recovery
and stability of rhBMP-2 in modified HBSS with added surfactant at 0.001% was
evaluated for three different concentrations (0.5, 5 and 15 µg/mL) outside the BIVDR
model initially. Table 4-6 shows the recovery and stability evaluations for rhBMP-2 in
modified HBSS media with added surfactant over two time points of 12 and 24 hrs.
respectively. Percentage recovery of rhBMP-2 in the modified HBSS media with added
surfactant was also examined at three different temperatures (37°C, 55°C, and 70°C) at
the end of a 5-day period incubation in a Nalgene tube (outside the BIVDR model).
Figure 4-17 shows the percentage recovery of rhBMP-2 in modified HBSS media for
three different temperatures compared with rhBMP-2 controls at day 0. A one-way
ANOVA with Dunnett’s multiple comparisons test was performed at a significance level
α=0.05. The specific temperature settings (37°C, 55°C, and 70°C) for each of the
corresponding 5-day incubated samples were compared with their control at day-0 to
observe if the means were significantly different. For the 37°C sample, the mean
recovery percentage for rhBMP-2 (in surfactant added media) in the 5-day sample was
not significantly different (p=0.9971). However, for the 55°C, and 70°C samples the
mean percentage recovery of rhBMP-2 (in surfactant added media) when compared to
day-0 sample were significantly different in both the cases: 55°C (p= 0.0365) and 70°C
(p= 0.0011).
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Once the stability evaluations for rhBMP-2 in the surfactant added media was
performed outside the BIVDR model, the next step, was to introduce the surfactant
added media to the BIVDR model (with the membranes) and observe the percentage
recovery. In the BIVDR model experimental set up with the introduction of 0.001% of
polysorbate 80 the percentage recovery with the RC membrane improved considerably.
With the RC membrane the total recovery percent from both the BRC and BPC
combined was observed to be 68.52 at 0.25hr., 93.20 at 6hr.,and 93.80 at 24 hr.
respectively. The lower recovery percent 0.25 hr. can be attributed to time taken by the
membrane to equilibrate with the rhBMP-2 solution. With the CA membranes the mean
recovery percentage of rhBMP-2 from both the chambers combined was observed to be
91.42 at 0.25hr, 95.99 at 6 hr and 83.02 at 24hr. The final recovery percentage for the
RC and CA membranes with added surfactant has been shown in Figure 4-18 and
Figure 4-19 respectively. It was observed during these experiments CA membrane
showed more variability in performance with regards to rhBMP-2 distribution between
the two chambers and lower recovery percentage as compared to RC membranes.
Therefore, regenerated cellulose membrane was selected as the membrane of choice in
surfactant added modified HBSS media for in vitro release experiments, to achieve
minimal variability and maximal recovery for the drug substance (rhBMP-2).
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Table 4-6. Recovery and stability of rhBMP-2 in modified HBSS with added surfactant
at 0.001%.
Nominal
Concentration
(µg/ml)

Modified HBSS media
(Recovery%)

Modified HBSS with
surfactant
(Recovery%)

12hr

24hr

12hr

24hr

Mean

93.71

98.43

95.06

94.12

SD

8.65

5.40

5.56

5.17

Mean

99.97

96.96

100.24

99.13

SD

1.36

3.59

2.54

3.21

Mean

99.96

98.96

100.21

99.76

SD

3.80

2.56

2.71

1.11

0.5 µg/ml

5 µg/ml

15 µg/ml
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Figure 4-17. Recovery percentage of rhBMP-2 in media with the addition of surfactant.
All statistical comparisons between samples (with day 0 as control) have been made
with ANOVA Dunnett’s multiple comparisons test. p <.05(*); p <.005(**).

139

Figure 4-18. Net recovery (BPC+BRC) of rhBMP-2 in the BIVDR model experimental
set up with the introduction of regenerated cellulose membrane with added surfactant of
0.001% polysorbate 80 in the media.
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Figure 4-19. Net recovery (BPC+BRC) of rhBMP-2 in the BIVDR model experimental
set up with the introduction of cellulose acetate membrane with added surfactant of
0.001% polysorbate 80 in the media.
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4.3.3 BIVDR model System Performance
The BIVDR model experimental set up comprising of the model, peristaltic pumps,
master flex platinized formulation tubings and three way flow valves worked seamlessly
over a period of 15 days. Visual observation was performed each day for detecting
presence of microorganisms. Sampling at each time point from the central chamber
(BPC) was followed by replacement of 1mL of the media unless the timepoints were too
close, e.g. during the first day (multiple time points). If more than two time points were
collected over a period of 6 hrs. 500 ± 50 µL of the media was sampled from the central
BPC. Sampling volume from the surrounding BRC was generally 1mL at each time point
(unless more than 1 time point was collected during the day). In such cases (more than
1 time point during the day) the sampling amount was 300 – 400 µL. Care was taken to
replace back the fresh media volume as accurately as possible with the help of
graduated piston syringes.

The flow rates of the peristaltic pumps were monitored every second day to avoid any
variability. The flow rates were kept at 0.8 – 0.9 mL/min. About one-third of the media
was replaced from the central BPC each day during sampling and one-eighth each day
from the surrounding BRC. Complete media replacement was done at the end of a 5
day run. pH of the media was also monitored from these 5 day samples and the
variability in pH was observed to be 7.1 ± 0.2. The small parts of the tubing wound
around the wheel of each of the low flow (0.03 -8.2 mL/min) VWR peristaltic pump were
the most fragile component of the experimental set up and required extra monitoring
and visual inspection. These special pump overhead tubings were observed to be prone
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to leakage. This was due to gradual development of perforations over the surface of the
overhead tubing, due to peristaltic pressure over a period of 7 days. The tubings in
these regions are required to be sensitive to pressure and too thick walled tubing would
not be able regulate the peristaltic low flow rates. It was thus a tradeoff between thin
walled tubings and tubing replacement every few days. Therefore, to avoid any media
leakage accidents overnight due to perforations, wear and tear the tubings were
replaced at the end of each 5th day (by stopping the flow with the help of three-way flow
valves after sampling). This helped ascertain the system was steady in its performance
and reduced chances of variability in data measurement.

4.3.4 Flow directionality selection in the BIVDR model
Figure 4-8 of this chapter in the methods section is a schematic representation of the
three flow directionality options in the BIVDR model, which can be achieved as a
function of alternating flow between the central BPC and surrounding BRC. In order to
determine i) if the directionality of flow would affect the release of rhBMP-2 from ACS
and ii) the most suitable flow direction (minimal variability) for the release of rhBMP-2
from ACS, an exploratory three day study at a flow rate of 0.8 -0.9 mL/min was
conducted with the three flow directions:
A) Flow in both the chamber (BPC + BRC)
B) Flow in only BRC (flow in BPC suspended)
C) Z patterned flow in diagonal ports of BRC.
Figure 4-20 shows the results of flow directionality effects on the release of rhBMP-2
from ACS. Each point represents the mean and standard deviation of n=3 experimental
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set ups. Table 4-7 shows the mean percentage cumulative drug released in vitro,
standard deviation and %RSD of the measurements for each flow directionality study at
24, 48 and 72hrs. time points in the BIVDR model. A paired samples t test was
conducted with pairwise alignment for each time point to compare the flow in (BPC +
BRC) with a) flow only in BRC and b) Z patterned flow in BRC. Since situation A (the
flow in both BPC + BRC) showed minimal variability (%RSD); it was selected as control
for each time point. There was no significant difference in percentage cumulative
release of rhBMP-2 for both the cases noted below:
a) flow in (BPC + BRC) with flow only in BRC; t (3) = 0.5058; p = 0.6748 (at a
significance level of α = 0.05) .
b) flow in (BPC + BRC) with Z patterned flow in BRC; t (3) = 2.505 ; p = 0.0873 (at
a significance level of α = 0.05) .
However, since scenario A (flow in both the chambers (BPC+BRC)) showed minimal
variability (%RSD) at each time point we decided to use it as the flow directionality
condition for the in vitro release experiments. This experiment also showed at a low flow
rate of 0.8 – 0.9 mL/min flow directionality does not significantly affect the release of
rhBMP-2 from ACS in the model. Higher flow rates need to be tested in future for other
implants requiring greater blood flow circulation in physiological environment for release
of drug substance.
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Figure 4-20. Flow directionality study in the chambers BPC and BRC.
The flow rate was maintained at 0.8 – 0.9 mL/min. The flow directionality have been
shown in detail in Figure 4-8. Each point represents mean and error bars represent SD
(n=3 experiments).
A paired sample t test was conducted at each time point with the flow with BPC and
BRC as control and a) Flow only in BRC and b) Z patterned flow at α = 0.05. There was
no significant difference (ns) in either case. a) Flow only in BRC: t (3) = 0.5058; p =
0.6478 b) Z patterned flow t (3) = 2.505; p = 0.0873
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Table 4-7. Flow directionality study for BIVDR model at 0.8 – 0.9 mL/min.

Mean
Flow directionality

(% Cumulative drug

SD

%RSD

released in vitro)
1. Flow in only BRC
24 hrs.

16.79

2.66

15.819

48hrs.

29.21

3.60

12.310

72hrs.

41.23

2.91

7.052

2. Flow in both BPC and BRC
24 hrs.

12.38

1.11

8.966

48hrs.

23.54

1.79

7.608

72hrs.

46.36

2.50

5.389

3. Z patterned flow (in only BRC flow ports)
24 hrs.

19.77

2.65

13.423

48hrs.

36.30

4.43

12.194

72hrs.

52.46

3.60

6.863
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4.3.5 Model cumulative release profiles
Drug release profiles can be plotted as either release rate profiles or percentage
cumulative drug release profiles. Release rate profiles are indicative of quantitative
pharmacokinetic parameters. These profiles are a function of time and their slopes
might often help us in the determination of pharmacokinetic parameters. Release rate
profiles especially in matrix assisted systems help in elucidation of the release behavior
at each phase of the multi-phasic system. Release rates can be calculated per hour or
per day depending upon the behavior of the dosage form.

Cumulative release profiles are particularly useful for matrix/scaffold assisted delivery
systems. In such systems the release of the active moiety/drug might be either diffusion
dependent or matrix erosion dependent or both. Such dosage forms often have complex
multi-phasic release. Cumulative release profiles are particularly applicable for such
polymer-based systems, during the initial phases of study where the intention might be
simply to determine the presence of net amount of drug released into the surrounding
(independent of mechanism of release). These profiles do not help us in the
determination of any pharmacokinetic parameters such as t1/2; AUC or MRT unless
they are converted and plotted. Neither does it help in the calculation of rate constants.
Percent cumulative drug release profiles on their own, without deconvolution, are not
elaborative of the kinetic order behavior of the drug. Such profiles are more for
qualitative determination rather than quantitative, if not converted or deconvoluted. The
information, which, they convey, is how much amount of drug is released over time.
However, some amount of drug behavior such as burst release phases and sustained
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released phases can be visually inspected to get a fair idea about the behavior of drug,
during early development phases. For many extended release complex dosage forms
with local delivery and a rapid rate of systemic clearance it is difficult to compare an in
vitro profile to in vivo profile with the help of pharmacokinetic parameters such as AUC,
t1/2 and MRT. In such cases an alternative approach for a release or dissolution test
would be to establish a simple, repeatable and predictable relationship of the in vitro
data with the in vivo data using techniques such as levy plots, time scaling/shifting and
making use of percent cumulative drug release profiles. The percentage cumulative
drug released vs. time in days for comparison of the three models a) sample and
separate b) USP-IV and c) BIVDR model has been shown in Figure 4-21A.

4.3.6 In vivo rat pharmacokinetic data
As mentioned in the methods section the rat pharmacokinetic data for the various
formulations a) INFUSE® Bone graft b) Osteograf N-300 were digitized using Engauge
digitizer and plotted using GraphPad Prism software. Figure 4-21B is a plot of the
percent cumulative drug release in vivo against the time in days for qualitative
visualization of the data. The profile has been adopted from the FDA submission of the
Safety and Effectiveness data of INFUSE® Bone Graft approved application and Uludag
et. al. 2005 (FDA Rockville, 2014; Medtronic, 2011; Uludag et al., 1999a). The profile
has been acquired by implantation in rat models. At each time point two rats were
sacrificed for obtaining the rhBMP-2 retained at the implant site. It had been shown that
the site of implantation of rhBMP-2: orthotopic site, femoral onlay model, subcutaneous
site did not
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Figure 4-21A. In vitro percentage cumulative drug released over time (days) for three
release study designs a) sample and separate b) USP-IV flow through cell c) BIVDR
model.
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Figure 4-21B. In vivo percentage cumulative drug released over time (days) for A)
INFUSE® Bone graft B) Osteograf N-300 in rat model.
(FDA Rockville, 2001, 2014; Uludag et al., 1999a)
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cause significant differences (>20%) in the release profile of rhBMP-2, since most of
these are deep seated osseous site and the pharmacokinetic parameters were ”found to
be in the same range” (Uludag et al., 2001). Analytical counts were calculated by
gamma (γ)- counted scintigraphy as radiolabelled 125I was used for tagging the rhBMP-2
protein. The release of rhBMP-2 was observed to be diffusion controlled in the range
of 0.8mg/ml - 2.0 mg/ml and was independent of concentration within this range.

4.3.7 Evaluation of a relationship between in vitro and in vivo
data
The in vivo data was obtained from Uludag and co-workers which compares the rhBMP2 release profiles between different carriers such as collagen sponge and
hydroxyapatite (Uludag et al., 1999a). This data and the in vivo data obtained from the
FDA submission document of INFUSE® Bone graft were digitized using Engauge
digitizer (FDA Rockville, 2014). The digitization of the data was also verified using
another software WebPlot digitizer. GraphPad Prism 7 and Microsoft excel was used for
the purposes of all data analysis. The cumulative release percent of rhBMP-2 from ACS
was plotted against time in days for all three models. The cumulative release percent of
rhBMP-2 from two different scaffolds were compared a) ACS in INFUSE® Bone Graft
and b) Osteograf N-300. It was observed that for the BIVDR model with ACS as the
scaffold a cumulative percent release of 88.40 ± 3.02 % occurred over a period of 6
days while for Osteograf N-300 a cumulative percent release of 76.94 ± 0.06 % was
observed. Figure 4-22 is a graphical representation of the percentage cumulative
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rhBMP-2 released over time in days for the two formulations INFUSE® Bone graft and
Osteograf N-300.
Figure 4-22. Percentage cumulative in vitro release of rhBMP-2 in BIVDR model from
two different formulations of rhBMP-2 a) INFUSE® Bone graft and b) Osteograf N-300.
Each time point represents n=3 data.
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4.3.7.1 Time scaling and Levy Plot:
In order to compare the in vivo and in vitro data it was essential to normalize the data on
the same time scale. This is called as time scaling. Time scaling is used as a tool when
the in vivo and in vitro data exhibit different release rates. The data was normalized with
the help of a Levy plot. A levy plot was created by plotting the in vitro dissolution/release
time of certain specific percentages on the X-axis (e.g. time taken to release 10%, 20%,
30% of the drug substance) vs. the time taken in vivo for absorption/release of similar
percentages of drug. Plotting the in vitro data against the in vivo data helped to
normalize the in- vitro data to the same time scale as in-vivo data. Time scaling and
time shifting parameters were obtained. The Levy’s plot has been shown in Figure 4-23.
The X-axis of the Levy plot in our current study shows the time taken in days for in vitro
cumulative release of rhBMP-2 in the BIVDR model. The Y-axis of the plot shows the
time taken in days for release of similar percentages in the in vivo Sprague Dawley rat
model. From the plot generated the time scaling factor was found to be 3.78 ±
0.238(SE) and a time shifting factor of 1.66 ± 0.768(SE) was calculated. The equation
can be represented in a Y=mX +C linear regression format as:
In vivo cumulative drug release time(days) =
3.777 (In vitro cumulative drug release time) - 1.662
With the help of the above equation the %cumulative in vitro release was plotted against
the % cumulative in vivo release with the time on the same scale now for both groups of
data. Figure 4-24A shows the evaluation of the in vitro in vivo relationship for the
rhBMP-2 release from ACS.
%Cumulative in vivo release = 1.005 (% cumulative in vitro release) +2.212
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Slope was observed to be 1.005 ± 0.05192 (SE). Y-intercept was 2.21 ± 3.138(SE)
The correlation coefficient was calculated to be 0.9816. The %prediction error for this
model was calculated by the formula:
%PE =[(Observed in vivo value – Predicted in vivo value)/ Observed value] X 100
(FDA Rockville, 1997). This was calculated to be 3.10% for INFUSE® Bone Graft using
the above IVIVR. Figure 4-24B shows the percentage cumulative in vivo data for the
observed and predicted rhBMP-2 release from ACS.
For the Osteograf N-300 a similar kind of time scaling/shifting was performed with the
help of the Levy’s plot (Figure 4-23) and a linear relationship between in vitro and in vivo
data was obtained. Figure 4-25A is a representative plot of the % cumulative in vitro
release against the % cumulative in vivo release. The parameters were evaluated
according to the equation stated below:
%Cumulative in vivo release = 1.036 (% cumulative in vitro release) – 3.341
Slope was observed to be 1.036 ± 0.06941(SE). Y-intercept was calculated as -3.341 ±
3.853(SE). The correlation coefficient was calculated to be 0.9824. The %prediction
error for this model was calculated by the formula:
%PE =[(Observed in vivo value – Predicted in vivo value)/ Observed value] X 100
This was calculated to be 1.11% for Osteograf N-300. Figure 4-25B shows the
percentage cumulative in vivo data for the observed and predicted rhBMP-2 release
from hydroxyapatite.
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Figure 4-23. Levy’s plot of cumulative in vivo drug release time (days) over cumulative
in vitro drug release time (days) to normalize the in vitro and in vivo data to the same
time scale.
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Figure 4-24A. Plots to show In vitro-in vivo relationship for rhBMP-2 release from ACS.
Slope was observed to be 1.005 ± 0.05192(SE). Y-intercept was 2.212 ± 3.138(SE)
The correlation coefficient was calculated to be 0.9816.

Figure 4-24B. Plots to show percentage cumulative in vivo observed and predicted in
vivo for rhBMP-2 release from ACS.
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Figure 4-25A. Plots to show In vitro in vivo relationship for rhBMP-2 release from
Osteograf N-300.
Slope was observed to be 1.036 ± 0.06941(SE). Y-intercept was calculated as -3.341 ±
3.853(SE). The correlation coefficient was calculated to be 0.9824.

Figure 4-25B. Plots to show percentage cumulative in vivo observed and predicted in
vivo for rhBMP-2 release from Osteograf.
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4.3.7.2 Discriminatory nature of the model
The discriminatory nature of the model was studied by using a model independent
approach. The model independent approach uses the calculation of a difference factor
(f1) and similarity factor (f2). f1 and f2 values are used to compare the experimental in
vivo and predicted in vivo data. They help in calculating a point-to-point comparison
between the experimental and predicted curve and determine the relative error between
them. For deciding if two formulations are equivalent or not FDA guidance on
dissolution tests for immediate dosage forms suggests an f1- difference value of less
than 15 and f2 – similarity factor values greater than 50.Though the equations given
below have been defined by FDA for immediate oral dosage forms they have been
applied in literature in relation to extended release dosage forms as in Burgess et. al for
determination of dexamethasone release from two different molecular weight PLGA
formulations (Shah et al., 1997; Zolnik and Burgess, 2008). The f1 and f2 equations for
calculation with a model independent approach have been shown below:

𝒇𝟏 =

𝒇𝟐 = 𝟓𝟎 ∗ 𝒍𝒐𝒈

𝒏
𝒕!𝟏 𝑹𝒕 ! 𝑻𝒕
𝒏
𝒕!𝟏 𝑹𝒕

𝟏! 𝟏 𝒏

𝒏
𝒕!𝟏

∗ 𝟏𝟎𝟎

𝑹𝒕 !𝑻𝒕 𝟐

!𝟎.𝟓

∗ 𝟏𝟎𝟎

In the above equations Rt is the cumulative percent release for the reference product or
formulation, which in current case is INFUSE® Bone graft and Tt, is the test product,
which in this research study is Osteograf N-300.
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Using the equations, a f1 (difference factor) value of 19.60 and a similarity factor f2 of
39.26 was calculated. For the model to be discriminatory between formulations an
f1 > 15 and f2 < 50 is required. This suggested the model was discriminatory between
the formulations. Table 4-8 shows the calculations for determination of f1 and f2 factor
using the BIVDR model.
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Table 4-8. f1 and f2 calculation for the reference product (INFUSE® Bone graft) and
test product (Osteograf N-300).

Time

Reference product (Rt)

Test product (Tt)

(days)

(INFUSE® )

(Osteograf N-300)

0.25

7.96

1.08

|𝑹𝒕 − 𝑻𝒕 |

(𝑹𝒕 − 𝑻𝒕 )𝟐

12.36

4.40

19.37

12.38

21.45

9.85

97.08

2

23.05

32.51

9.47

89.67

3.79

55.53

63.97

13.80

190.35

6

88.40

76.94

8.66

74.99

7

88.86

77.45

11.41

130.20

8

91.21

78.20

14.40

207.36

𝒏
𝒕!𝟏

𝑹𝒕 − 𝑻𝒕
𝒏
𝒕!𝟏

𝒏
𝒕!𝟏

𝑹𝒕

367.38

𝑹𝒕 − 𝑻𝒕

Difference factor: 𝒇𝟏 =

Similarity factor: 𝒇𝟐 = 𝟓𝟎 ∗ 𝒍𝒐𝒈

71.99

809.14

𝟐

𝒏 𝑹 !𝑻
𝒕
𝒕!𝟏 𝒕
𝒏 𝑹
𝒕!𝟏 𝒕

𝟏! 𝟏 𝒏

𝒏
𝒕!𝟏

∗ 𝟏𝟎𝟎

!𝟎.𝟓
𝑹𝒕 !𝑻𝒕 𝟐
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19.60

∗ 𝟏𝟎𝟎

39.26

4.3.8 Advantages and limitations of the study
The current research study had its own set of advantages and limitations. During the
development of the in vitro release study design we faced some challenges while
gathering in vivo data from literature particularly with respect to data for formulations of
rhBMP-2 not involving INFUSE® Bone graft. A limitation of this study is the rat
pharmacokinetic data obtained by digitization of Uludag et. al, 1999 involved
radiolabelled quantitation methods for in vivo time points (Uludag et al., 1999a).
35

125

I and

S radiolabelled rhBMP-2 was used in the implants and γ and β- scintillation counters

were used for calculating the radioactive counts for rhBMP-2 protein retained in the
implant. At each time point two rats were sacrificed and the implants were extracted to
calculate the retention of rhBMP-2 in the sponge (Uludag et al., 1999a) . While using the
in vivo data we converted the in vivo percentage retention in ACS to in vivo percentage
released. However, since destructive sampling was not a feasible option while
developing an in house in vitro release study design we developed and validated a
HPLC-UV method for the quantitation of rhBMP-2 in the release media. Although ELISA
was used for quantitation during sample & separate and USP-IV, the release profiles
were incomplete and non-representative of the in-vivo profiles for these methods and
hence cross-validation was not necessary due to distinct differences in cumulative
release in vitro profiles. Validation and stability analysis was evaluated in detail for the
HPLC method in regards to precision, accuracy, selectivity, stability of rhBMP-2 in
release media. This helped reduce the chances of our analytical methodology
introducing any additional variability into the release study design and data. The in vitro
release study design therefore helped us to avoid a destructive sampling mechanism at
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each time point. Although this was time and cost efficient and one of the goals of
developing the in vitro release study design was to avoid the path of destructive
sampling we were mindful that during this study we are comparing the percentage
cumulative drug release profiles obtained using two different analytical methods:
radiolabelled counting for in vivo rat PK data and HPLC method for in vitro release data.
In evaluation of the discriminatory profile of the BIVDR model between the reference
(INFUSE® ) and test (Osteograf) product we use similarity factor (f2) as a parameter.
While Polli and co-workers, in 1997 have evaluated the significance of f2 factor and its
accuracy and applicability in dissolution study designs; the f2 factor gets affected by the
“length of the dissolution profile” as mentioned in Pillay et. al, 1998 (Moore, 1996; Pillay
and Fassihi, 1998; Polli et al., 1997). In the current research investigation we have
attempted to reach a cumulative drug release percentage of > 80% as is suggested in
the FIP/AAPS guidelines for novel dosage forms (Siewert et al., 2003). This helps us
achieve a comprehensive release profile bracketing the different phases of the complex
dosage form. Another limitation of the study is the in vivo sampling time points which
are available for formulation carriers for rhBMP-2 other than INFUSE® Bone graft have
only four time points. For developing a successful IVIVR and a Levy’s plot atleast 6 time
points are required. Interpolation of two additional time point was required for the
Osteograf N-300. This was performed between 0.44 day and 3.35 days: the first two
time point for in vivo rat data; since the data was extremely sparse in this region and not
evenly distributed. The sparse data points for the second formulation (Osteograf)
therefore also posed a challenge in development of an evaluative In Vitro Relationship
(IVR).
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4.4 Conclusion
A step-by-step modular approach was adopted while designing the biorelevant in vitro
drug release (BIVDR) model. Since our drug substance was a protein, which showed
adsorption to conventional glass models such as USP-IV flow through cells, to make the
model adaptable and deliver the best drug recovery percentage, each design
component was tested for its adsorption to the protein component. The net recovery of
the protein with the introduction of each specific component into the model was
evaluated, and only then the design component was introduced into the BIVDR system.
In vivo fluid inorganic ion concentration, osmolality, pH and temperature were simulated
in the experimental set up. Flow directionality and flow ports were designed to simulate
in vivo tissue vascularity. The flow ports were also designed to not subject the dosage
form to be placed perpendicularly in the path of flow. Because of the presence of a
centralized core compartment with membranes at both ends, the BIVDR model can also
be applied for release or dissolution testing of complex dosage forms such as
liposomes, nanoparticles and microspheres. There is physical separation of the dosage
form from the other compartments with the help of porous filter membranes. The porous
membranes allow for free exchange of media between compartments but limit the
carrier scaffold of the dosage form within the core compartment. This helps in providing
better sampling capabilities and no extra steps in physical separation of the dosage
form and media is required at each sampling time point. We hope that the application of
this model can be extended to dissolution and release testing of similar controlled
release parenterals and protein based dosage forms.
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CHAPTER 5

5 SUMMARY AND GENERAL CONCLUSIONS

Drug formulation development has improved enormously over the past few decades.
This has enabled targeted local drug delivery to complex physiological sites. Drug
delivery systems have also seen an unparalleled growth. The active drug substance is
no longer just a small molecule or chemical entity (200 - 2000Da); it can be a large
molecule or protein (10 -150kDa). Biotechnology and genetic engineering has facilitated
the development of recombinant ‘orthobiologics’. ‘Orthobiologics’ are recombinant
biologic products often having the same composition as a human endogenous protein
but produced in other pre-clinical species or cell lines (such as Chinese Hamster Ovary
cell lines) with the help of genetic engineering and recombinant DNA technology. The
interplay of all these factors have also given rise to drug modalities that are able to
deliver the active drug substance targeted at almost any location of the human body
with a) minimal immunogenicity and b) controlled release over an extended period of
time. Extended controlled release drug formulations often called as ‘novel’ dosage
forms help in maintaining therapeutic levels of the drug substance and ensure patient
compliance (Burgess et al., 2004; Burgess et al., 2002b).
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In vitro dissolution and release tests are a part of the public specification tests of a
dosage form. Their most significant use is in the SUPAC stages and for achieving
biowaivers (clinical stages). However, a well-developed biorelevant release study
design can also be used during the formulation development stages (pre-clinical
stages). In many ‘complex’ dosage forms obtaining pharmacokinetic data from humans
can be difficult even during clinical stages of the drug e.g. INFUSE® Bone graft, ocular
implants. These implants generally carry drugs in their carriers targeted at local tissues
and sites of healing and often have high rates of systemic clearance. Protein and
peptide based drugs often show receptor mediated clearance -internalization /
opsonization mechanisms of clearance (catabolic clearance) and do not follow the
typical hepatic or renal clearance route (Chirmule et al., 2012). This also makes their
elimination rates extremely variable. The biodistribution of these drugs at the local nonaccessible tissue chambers enhances the dilemma of generating pharmacokinetic
profiles in humans. ‘Biorelevant’ in vitro release tests can help with such ‘novel’ multichambered drug biodistribution study designs. These in vitro release tests add to the
study design a combination of i) clinically relevant easy to reproduce media, ii) modular
design of the release apparatus and iii) well researched biorelevant parameters
represented in the study design with a robust analytical method.
The current research investigation focuses on the development of such an approach.
The primary objective of this research was to design an in vitro release test that would
be optimized for a ‘complex’ carrier based implant with a protein as the active
pharmaceutical ingredient.
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In Chapter 3 of the thesis a stability indicating HPLC-UV method was developed and
validated for the quantitation of drug substance in this media. The media was
comparable to plasma in terms of inorganic ion concentrations, osmolality, pH, buffering
capacity with respect to temperature changes (Iyer et al., 2007b). The dynamic range of
the method was from 0.50 -100 µg/mL with a %DFN of 9.67% at the LLOQ (0.50 µg/mL)
to – 6.27%. The LOD for the method was 0.10 µg/mL. Stability of the drug was also
determined in the media at 37°C, room temperature 22°C and at autosampler analysis
temperature 4°C, at low and medium concentration level of 2 µg/mL and 15 µg/mL
respectively. The stability percentages were found to be within the permissible range of
90-110%. In addition to the stability studies presence of interfering excipients and
degradant peaks during the in vitro release test were investigated with the help of
acidic, basic, oxidation and temperature based forced degradation analysis for 72hrs.
The degradant peaks were trapped and injected into LC-MS/MS for qualitative
characterization of the changes occurring to the protein molecule (oxidative
degradation, deamidation of N terminal end and hydrolysis). The robustness of the
method was also explored with inter and intra day accuracy and precision (%RSD within
± 10%), and system suitability for precision, retention time and tailing factor of multiple
injections (n=6). The %RSD was found to be within ± 1.75%.
Chapter 4 of this research study focused on the primary objective of this research of
developing a biorelevant in vitro release test for a ‘complex’ dosage form. This was
performed by setting up a simple sample and separate with INFUSE® Bone graft. A
cumulative release profile with a release percentage of 58.89 ± 4.97 % over 30 days
was obtained for the sample and separate. An asymptote was observed in the
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cumulative release profile after the first 15 days and drug release > 80% could not be
achieved with this system. The next approach was to use the USP guideline suggested
USP-IV flow through cell apparatus. For the USP-IV model the cumulative release
profile showed an apparent asymptote after the first 15min of approximately 15% burst
release and negligible release was observed for up to 5 days. USP-IV helped us
investigate a step further the effects of:
i)

flow rates and flow directionality on the fragile, shear labile collagen sponge
carrier based dosage form

ii)

nature of the cell container material (glass) on the active pharmaceutical
ingredient (rhBMP-2 protein) recovery.

As a result, on visual inspection the placement of the dosage form (absorbable
collagen sponge scaffold with the rhBMP-2 protein) also showed pieces of the scaffold
being torn away and in the circulation even at reduced flow rates of 0.8 – 0.9 mL/min.
Such a release study design also gives rise to chances of enhanced variability. Our
observation was that, this occurred due to the fragile dosage form being placed
perpendicularly in the path of flow. From our literature review, we know that the sinus
augmentation cavity is innervated by blood vessels that have flow rates of 0.8 - 0.9
mL/min. The dosage form is not placed perpendicularly on the path of flow during the
sinus augmentation surgery by the clinician. Therefore, in order to make the release
study design more clinically relevant and less variable we incorporated all these factors
to have an improved biorelevant in vitro release test.
A novel biorelevant in vitro drug release (BIVDR) model was designed for implant based
dosage forms with novel construction and adapatability with the following components:
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i)

Low protein adsorption material – Body of the model was constructed with the
material (polycarbonate) having minimal protein (rhBMP-2) adsorption and
maximal recovery thereby helping to reduce variability in cumulative release
profiles as compared to USP-IV apparatus.

ii)

Multi-chambered model – the BPC and BRC helped to allow for physical
segregation of the fragile dosage form from the media to help in sampling and
media replacement at each time point. The chambers were separated by
porous regenerated cellulose or cellulose acetate membranes (also optimized
for minimal rhBMP-2 adsorption and maximal recovery with minimal
variability). The membranes allowed free diffusion of the rhBMP-2 molecule
between chambers while keeping the carrier scaffold in the centralized BPC.

iii)

Flow ports and flow directionality – Each chamber the BPC and BRC had flow
ports, which, were placed parallel to the directionality of the dosage form. This
simulated physiological blood vessel enervation and also reduced scaffold
tearing off due to flow of fluid.

iv)

Low volumes – The chambers were designed to simulate implant
physiological microenvironment of low fluid surrounding area. The central
core compartment (BPC) had a volume of 2.99mL and the surrounding
compartment (BRC) had a volume of 8mL. The core compartment’s (BPC)
height and width was designed to simulate the average physiological pocket
of the maxillary sinus cavity during sinus augmentation or lift surgeries (net
volume 2-3 mL).
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Apart from these features, the other biorelevant parameters included in the study design
were the pH and osmolarity of the media, and physiological body temperature 37°C.
With these components incorporated in the study design we obtained cumulative
percent release profiles of > 80% release of rhBMP-2 from the ACS scaffold in the
BIVDR model. Time scaling was performed to achieve normalization of the in vitro and
in vivo data on the same time scale with a levy plot. The time scaling factor was 3.77
with a R2 value of 0.97 for release percentages from 10% to 80% of rhBMP-2 from ACS.
With these factors the In vitro in vivo relationship was evaluated and found to be:
%Cumulative in vivo release = 1.005 (% cumulative in vitro release) +2.212
with a correlation coefficient of 0.9816.
In order to observe if the model was discriminatory between formulations Osteograf N300 a hydroxyapatite based carrier scaffold for rhBMP-2 was also evaluated. The IVIVR
was calculated to be
%Cumulative in vivo release = 1.036 (% cumulative in vitro release) – 3.341
with a correlation coefficient of 0.9824. Similarity (f2) and difference (f1) factors were
used for calculating the difference between the two formulations a) collagen carrier
scaffold and b) hydroxyapatite-based scaffold of rhBMP-2 drug substance. A value of
39.26 and 19.60 was obtained for the similarity and difference factors respectively
showing discriminatory release profiles for the BIVDR model and the release study
design.
Future application of the model: The BIVDR model has been designed for the in vitro
release testing of ‘special’ dosage forms such as liposomes, microspheres or any fragile
carrier based implant. Generally implants are physiologically in surrounding low fluid
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volumes. The net volume of the model is 11 mL with the central BPC and surrounding
BRC. If required an additional chamber SC can be screwed in to add 2mL of fluid
volume. This chamber can then be used for simulating a different tissue fluid and
observing the distribution into this chamber. This king of multi-chambered approach
would also help for observing and studying biodistribution into tissue chambers (e.g.
ocular chamber: vitreous humor) for complex dosage forms (such as for ocular
implants) with controlled delivery using lipid nano-particles carrying drugs like
dexamathasone (Souto et al., 2010; Xu et al., 2000). Another major advantage of the
model is physical segregation of the dosage form in the BPC compartment with flow
ports designed to enable media flow over and under the porous chamber. This would
greatly facilitate sampling for dosage forms like microspheres, liposomes e.g. controlled
delivery of proteins using PLGA, polyanhydride, chitosan microspheres (Cohen et al.,
1991; Jameela et al., 1998; Tabata et al., 1993). The validated BIVDR model system
has not used its full capability of multi-chambers (including the sinus chamber (SC) or
utilization of different osmolality media in each chamber. Therefore, more data is
required to be collected with diverse novel dosage forms to know how well the model
performs. For our research investigation, we applied two implant based formulations of
the rhBMP-2 drug substance and were able to develop a discriminatory and predictive
relationship. We hope to use the model for other peptide and protein based parenteral
formulations. The design of the model would help support the investigation of release
profiles of ‘complex’ dosage forms.
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